Author: "writing of the manuscript" / Topic: medicine - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"writing of the manuscript"' showing total 35 results

Start Over Author "writing of the manuscript" Topic medicine

35 results on '"writing of the manuscript"'

1. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity

Author: Volta U, Bardella MT, Calabrò A, Troncone R, Corazza GR, Study Group for Non Celiac Gluten S.e.n.s.i.t.i.v.i.t.y. Authors’ contributions UV: Study design, clinical evaluation, enrollment of patients, data analysis, writing of the manuscript, final s.u.p.e.r.v.i.s.i.o.n. MTB: Study design, final supervision of the m.a.n.u.s.c.r.i.p.t. AC, RT: Study design, final supervision of the m.a.n.u.s.c.r.i.p.t. GRC: Study design, final supervision of the m.a.n.u.s.c.r.i.p.t. All authors read, approved the final m.a.n.u.s.c.r.i.p.t. The Study Group for Non Celiac Gluten Sensitivity, included Carmela Bagnato, Claudio Belcari, Antonella Bellantoni, Giacomo Caio, Francesca Calella, Maria Cappello, Carolina Ciacci, Cinzia D’Agate, Italo De Vitis, Antonio Di Sabatino, Gianmarco Fava, Maria Rita Frau, Alessandro Fugazza, Stefano Andrea Grassi, Giuseppina Larcinese, Giovanni Latella, Adriano Lauri, Angelo Lauria, Nicoletta Lenoci, Norma Beatriz Lopez Rios, Donatella Macchia, Mauro Minelli, Beba Molinari, Olivia Morelli, Maria Gloria Mumolo, Giovanni Niccoli, Caterina Pacenza, Francesco Pallone, Fabrizio Parente, Raffaella Pulitanò, Rossella Pumpo, Antonio Rispo, Flavio Romolo Rispoli, Francesco Tedone, Flavio Valiante, Giovanni Viviani, Paolo Usai S.a.t.t.a. All these authors performed clinical evaluation, as well as final supervision of the manuscript, RIEGLER, Gabriele, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Da definire, Volta U, Bardella MT, Calabrò A, Troncone R, Corazza GR, Study Group for Non-Celiac Gluten Sensitivity, Volta, U, Bardella, Mt, Calabrò, A, Troncone, R, Corazza, Gr, Authors’ contributions UV: Study design, Study Group for Non Celiac Gluten S. e. n. s. i. t. i. v. i. t. y., Clinical, Evaluation, enrollment of, Patient, Data, Analysi, writing of the, Manuscript, MTB: Study design, final s. u. p. e. r. v. i. s. i. o. n., final supervision of the m. a. n. u. s. c. r. i. p. t., Ac, RT: Study, Design, GRC: Study design, final supervision of the m. a. n. u. s. c. r. i. p. t., All authors read, final supervision of the m. a. n. u. s. c. r. i. p. t., The Study Group for Non Celiac Gluten Sensitivity, approved the final m. a. n. u. s. c. r. i. p. t., included Carmela, Bagnato, Claudio, Belcari, Antonella, Bellantoni, Giacomo, Caio, Francesca, Calella, Maria, Cappello, Carolina, Ciacci, Cinzia, D’Agate, Italo De, Viti, Antonio Di, Sabatino, Gianmarco, Fava, Maria Rita, Frau, Alessandro, Fugazza, Stefano Andrea, Grassi, Giuseppina, Larcinese, Giovanni, Latella, Adriano, Lauri, Angelo, Lauria, Nicoletta, Lenoci, Norma Beatriz Lopez, Rio, Donatella, Macchia, Mauro, Minelli, Beba, Molinari, Olivia, Morelli, Maria Gloria, Mumolo, Giovanni, Niccoli, Caterina, Pacenza, Francesco, Pallone, Fabrizio, Parente, Raffaella, Pulitanò, Rossella, Pumpo, Riegler, Gabriele, Antonio, Rispo, Flavio Romolo, Rispoli, Francesco, Tedone, Flavio, Valiante, Giovanni, Viviani, All these authors performed clinical evaluation, Paolo Usai S. a. t. t. a., as well as final supervision of the, Manuscript, and The Study Group for Non-Celiac Gluten, Sensitivity
Subjects: Male, Abdominal pain, Constipation, Gastrointestinal Diseases, Non-celiac gluten sensitivity, FODMAP, prospective survey, Intestinal mucosa, Anti-gliadin antibodies, Celiac disease, Clinical picture, Duodenal biopsy, Prospective survey, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Celiac Disease, Child, Child, Preschool, Diet, Gluten-Free, Female, Food Hypersensitivity, Glutens, HLA-DQ Antigens, Humans, Intestinal Mucosa, Italy, Middle Aged, Prevalence, Prospective Studies, Sex Factors, Surveys and Questionnaires, Young Adult, Medicine (all), Diagnosis, 80 and over, Irritable bowel syndrome, Medicine(all), biology, General Medicine, Multicenter study, Gluten-free diet, medicine.symptom, medicine.medical_specialty, CELIAC DISEASE, celiac disease, gluten, non celiac gluten sensitivity, digestive system, NO, Bloating, Internal medicine, medicine, Preschool, business.industry, nutritional and metabolic diseases, medicine.disease, digestive system diseases, Diet, Food intolerance, Immunology, biology.protein, Commentary, Gluten-Free, Gluten free, business, Gluten
Abstract: none 6 no Background: Non-celiac gluten sensitivity (NCGS) is still an undefined syndrome with several unsettled issues despite the increasing awareness of its existence. We carried out a prospective survey on NCGS in Italian centers for the diagnosis of gluten-related disorders, with the aim of defining the clinical picture of this new syndrome and to establish roughly its prevalence compared with celiac disease. Methods: From November 2012 to October 2013, 38 Italian centers (27 adult gastroenterology, 5 internal medicine, 4 pediatrics, and 2 allergy) participated in this prospective survey. A questionnaire was used in order to allow uniform and accurate collection of clinical, biochemical, and instrumental data. Results: In total, 486 patients with suspected NCGS were identified in this 1-year period. The female/male ratio was 5.4 to 1, and the mean age was 38 years (range 3–81). The clinical picture was characterized by combined gastrointestinal (abdominal pain, bloating, diarrhea and/or constipation, nausea, epigastric pain, gastroesophageal reflux, aphthous stomatitis) and systemic manifestations (tiredness, headache, fibromyalgia-like joint/muscle pain, leg or arm numbness, 'foggy mind,' dermatitis or skin rash, depression, anxiety, and anemia). In the large majority of patients, the time lapse between gluten ingestion and the appearance of symptoms varied from a few hours to 1 day. The most frequent associated disorders were irritable bowel syndrome (47%), food intolerance (35%) and IgE-mediated allergy (22%). An associated autoimmune disease was detected in 14% of cases. Regarding family history, 18% of our patients had a relative with celiac disease, but no correlation was found between NCGS and positivity for HLA-DQ2/-DQ8. IgG anti-gliadin antibodies were detected in 25% of the patients tested. Only a proportion of patients underwent duodenal biopsy; for those that did, the biopsies showed normal intestinal mucosa (69%) or mild increase in intraepithelial lymphocytes (31%). The ratio between suspected NCGS and new CD diagnoses, assessed in 28 of the participating centers, was 1.15 to 1. Conclusions: This prospective survey shows that NCGS has a strong correlation with female gender and adult age. Based on our results, the prevalence of NCGS seems to be only slightly higher than that of celiac disease. none Volta U;Bardella MT;Calabrò A;Troncone R;Corazza GR;Study Group for Non-Celiac Gluten Sensitivity Volta U;Bardella MT;Calabrò A;Troncone R;Corazza GR;Study Group for Non-Celiac Gluten Sensitivity
Published: 2014

2. Atopy modifies the association between inhaled corticosteroid use and lung function decline in patients with asthma

Author: Isabelle Pin, Isa Cerveri, Lucia Cazzoletti, Andrei Malinovschi, Josep M. Antó, Simone Accordini, Deborah Jarvis, David Gislason, Ane Johannessen, Bénédicte Leynaert, Pierpaolo Marchetti, Diogenes S. Ferreira, Nicole Probst-Hensch, Alessandro Marcon, Christer Janson, Rain Jögi, Judith Garcia-Aymerich, Angelo Corsico, Joachim Heinrich, Joost Weyler, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 2610, 4350 97/0035-01, 99/0034-01, 99/0034-02 97/0035, 97/0035-02, 99/0034-04, 99/0034-06, 99/0034-07, 99/350 90MR/10, 91AF/6 SEPAR R01 HL62633-01 018996 911631 Russell Sage Foundation, RSF ResMed Foundation AstraZeneca GlaxoSmithKline, GSK Novartis U.S. Public Health Service, USPHS: R01 HL62633-01 Chiesi Farmaceutici, Chiesi Faculty of Arts and Sciences, Harvard University, FAS Boehringer Ingelheim VÃ¥rdalstiftelsen Freiwillige Akademische Gesellschaft, FAG Commercial Aircraft of China, COMAC Wellcome Trust, WT: WT 084703MA Horizon 2020 Framework Programme, H2020: 633212 Growing Spine Foundation, GSF Gobierno del Principado de Asturias Blond McIndoe Research Foundation, BMRF Asthma and Allergy Foundation of America, AAFA Ministerio de Sanidad, Consumo y Bienestar Social, MISAN Union Chimique Belge, UCB Medical Research Council, MRC: 92091, G0901214 National Institute for Health Research, NIHR British Lung Foundation, BLF European Commission, EC: EU-PEAL PL01237 National Health and Medical Research Council, NHMRC: G.0402.00 Asthma Foundation of Victoria Deutsche Forschungsgemeinschaft, DFG: FR1526/1-1, HE 3294/10-1, MA 711/4-1, MA 711/6-1, NO 262/7-1 Agence Nationale de la Recherche, ANR Schweizerischer Nationalfonds zur FÃ¶rderung der Wissenschaftlichen Forschung, SNSF: 3100-059302, 3200-042532, 3200-052720, 3247-065896, 3247BO-104283, 3247BO-104284, 3247BO-104288, 33CSCO-108796, 33CSCO-134276/1, 4026-028099, 4026-28099 Eesti Teadusfondi, ETF: 1088 ForskningsrÃ¥det fÃ¶r Arbetsliv och Socialvetenskap, FAS Eesti Teadusagentuur: 562 Bundesamt für Gesundheit, BAG Belgian Federal Science Policy Office, BELSPO Generalitat de Catalunya Consell CatalÃ de Recerca i InnovaciÃ³: 1999SGR 00241 Haridus- ja Teadusministeerium: SF0180060s09 HjÃ¤rt-Lungfonden Consiglio Nazionale delle Ricerche, CNR Instituto de Salud Carlos III, ISCIII: C03/011, C03/09 HÃ¡skÃ³li Ãslands, HI Norges ForskningsrÃ¥d: 101422/310, 214123 Medicinska ForskningsrÃ¥det, MFR Cancéropôle Ile de France Russian Science Foundation, RSF: 381/05.93 Ministeriet Sundhed Forebyggelse SUVA Sociedad Española de Neumología y Cirugía Torácica, SEPAR: FIS 09/01511, FIS PS09/00716, FIS PS09/02185, FIS PS09/03190, SEPAR 1001/2010 Horizon 2020 Universiteit Antwerpen ComitÃ© des Maladies Respiratoires de l'IsÃ¨re ComissiÃ³ Interdepartamental de Recerca i InnovaciÃ³ TecnolÃ²gica, CIRIT: 1997 SGR 00079, 1999 SGR 00214 Servicio Murciano de Salud Regione del Veneto Regione Piemonte Astma- och AllergifÃ¶rbundet Centre Hospitalier Universitaire de Bordeaux, CHU de Bordeaux Office FÃ©dÃ©ral de l'Education et de la Science, OFES Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie, BMBWF Helmholtz Zentrum MÃ¼nchen Lungenliga Schweiz Ministerio de Medio Ambiente y Medio Rural y Marino, MARM: G03/176 Ministère des Solidarités et de la Santé INCLIVA Instituto de Investigación Sanitaria: 91/0016-060-05/E, 92/0319, 93/0393, PS09/00716, PS09/01511, PS09/02185, PS09/02457, PS09/03190 Fundació Autònoma Solidària, FAS Servicio Andaluz de Salud, SAS, The ALEC study is funded by the European Union's Horizon 2020 Research and Innovation programme under grant agreement number 633212. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. National funders who supported data collection in the original studies are listed in Appendix E4 in this article's Online Repository at www.jaci-inpractice.org. The funders had no role in the writing of the manuscript or the decision to submit it for publication.Conflicts of interest: D. S. Ferreira reports grants from the Asthma Foundation of Victoria, Allen and Hanburys, National Health and Medical Research Council. I. Pin reports travel grants and honoraria from Novartis, Zambon, and AstraZeneca, and nonfinancial support from AGIR?dom. R. J?gi reports grants from Estonian Research Council Personal Research (grant no. 562), and consultancy, lecture, and travel fees from GlaxoSmithKline, Boehringer, and Novartis. The rest of the authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.Financial support for ECRHS I: The coordination of this work was supported by the European Commission, and the authors and participants are grateful to the late C. Baya and M. Hallen for their help during the study and K. Vuylsteek and the members of the COMAC for their support. The following grants helped to fund the local studies: Australia: Asthma Foundation of Victoria, Allen and Hanbury's, Belgium: Belgian Science Policy Office, National Fund for Scientific Research, Estonia: Estonian Science Foundation (grant no. 1088), France: Minist?re de la Sant?, Glaxo France, Institut Pneumologique d'Aquitaine, Contrat de Plan Etat-R?gion Languedoc-Rousillon, Caisse nationale de l'assurance maladie des travailleurs salari?s, Comit? national contre les maladies respiratoires et la tuberculose (90MR/10, 91AF/6), Ministre delegu? de la sant?, R?seau national de sant? publique, France, Germany: Helmholtz Zentrum Munich and Bundesminister f?r Forschung und Technologie, Italy: Ministero dell'Universit? e della Ricerca Scientifica e Tecnologica, Consiglio Nazionale delle Ricerche, Regione Veneto (grant RSF no. 381/05.93), Norway: Norwegian Research Council project no. 101422/310, Portugal: Glaxo Farmac?utica Lda, Sandoz Portugesa, Spain: Fondo de Investigaci?n Sanitaria (nos. 91/0016-060-05/E, 92/0319, and 93/0393), Hospital General de Albacete, Hospital General Juan Ram?n Jim?nez, Direcci?n Regional de Salud P?blica (Consejer?a de Sanidad del Principado de Asturias), Consell Interdepartamental de Recerca i Innovaci? Tecnol?gica (1997 SGR 00079), and Servicio Andaluz de Salud, Sweden: The Swedish Medical Research Council, the Swedish Heart-Lung Foundation, the Swedish Association against Asthma and Allergy, Switzerland: Swiss National Science Foundation (grant no. 4026-28099), and UK: National Asthma Campaign, British Lung Foundation, Department of Health, South Thames Regional Health Authority.Financial support for ECRHS II: Australia: National Health and Medical Research Council, Belgium: Antwerp: Fund for Scientific Research (grant code G.0402.00), University of Antwerp, and Flemish Health Ministry, Estonia: Tartu: Estonian Science Foundation (grant no. 4350), France: (All) Programme Hospitalier de Recherche Clinique?Direction de la Recherche Clinique de Grenoble 2000 number 2610, Ministry of Health, Minist?re de l'Emploi et de la Solidarit?, Direction G?nerale de la Sant?, Centre Hospitalier Universitaire de Grenoble, Bordeaux: Institut Pneumologique d'Aquitaine, Grenoble: Comite des Maladies Respiratoires de l'Isere, Montpellier: Aventis (France), Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon, Paris: Union Chimique Belge-Pharma (France), Aventis (France), Glaxo France, Germany: Erfurt: GSF?National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code FR1526/1-1), Hamburg: GSF?National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code MA 711/4-1), Iceland: Reykjavik: Icelandic Research Council and Icelandic University Hospital Fund, Italy: Pavia: GlaxoSmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), and Local University Funding for Research 1998 and 1999, Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico?Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Verona: Ministero dell'Universit? e della Ricerca Scientifica (MURST), Glaxo Wellcome s.p.a., Norway: Bergen: Norwegian Research Council, Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, and Norway Research Fund, Spain: Fondo de Investigacion Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Hospital Universitario de Albacete, Consejeria de Sanidad, Barcelona: Sociedad Espanola de Neumolog?a y Cirug?a Toracica, Public Health Service (grant code R01 HL62633-01), Fondo de Investigaciones Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Consell Interdepartamentalde Recerca i Innovaci? Tecnol?gica (grant code 1999SGR 00241), Instituto de Salud Carlos III, Red de Centros de Epidemiolog?a y Salud P?blica, C03/09, Red de Bases moleculares y fisiol?gicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176, Huelva: Fondo de Investigaciones Santarias (grant codes 97/0035-01, 99/0034-01, and 99/0034-02), Galdakao: Basque Health Department, Oviedo: Fondo de Investigaciones Sanitaria (97/0035-02, 97/0035, 99/0034-01, 99/0034-02, 99/0034-04, 99/0034-06, 99/350, and 99/0034-07), European Commission (EU-PEAL PL01237), Generalitat de Catalunya (CIRIT 1999 SGR 00214), Hospital Universitario de Albacete, Sociedad Espa?ola de Neumolog?a y Cirug?a Tor?cica (SEPAR R01 HL62633-01), Red de Centros de Epidemiolog?a y Salud P?blica (C03/09), Red de Bases moleculares y fisiol?gicas de las Enfermedades Respiratorias (C03/011), and Red de Grupos Infancia y Medio Ambiente (G03/176, 97/0035-01, 99/0034-01, and 99/0034-02), Sweden: G?teborg, Umea, AND Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation, and Swedish Council for Working Life and Social Research (FAS), Switzerland: Basel: Swiss National Science Foundation, Swiss Federal Office for Education and Science, and Swiss National Accident Insurance Fund, UK: Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign).Financial support for ECRHS III: Australia: National Health and Medical Research Council, Belgium: Antwerp: South and Antwerp City: Research Foundation Flanders (grant code G.0.410.08.N.10), Estonia: Tartu: the Estonian Ministry of Education (SF0180060s09), France: (All): Minist?re de la Sant?, Programme Hospitalier de Recherche Clinique national 2010, Bordeaux: INSERM U897 Universit? Bordeaux segalen, Grenoble: Comite Scientifique AGIRadom 2011, and Paris: Agence Nationale de la Sant?, R?gion Ile de France, domaine d'int?r?t majeur, Germany: Erfurt: German Research Foundation (HE 3294/10-1), Hamburg: German Research Foundation (MA 711/6-1, NO 262/7-1), Iceland: Reykjavik: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation, California, USA, Orkuveita Reykjavikur (Geothermal plant), and Vegager?in (The Icelandic Road Administration, Italy: All Italian centers were funded by the Italian Ministry of Health, Chiesi Farmaceutici SpA, in addition, Verona was funded by Cariverona Foundation and Education Ministry (Ministero dell'Istruzione, dell'Universit? e della Ricerca), Norway: Norwegian Research Council (grant no. 214123), Western Norway Regional Health Authorities (grant no. 911631), and Blond McIndoe Research Foundation, Spain: Fondo de Investigaci?n Sanitaria (PS09/02457, PS09/00716, PS09/01511, PS09/02185, PS09/03190), Servicio Andaluz de Salud, Sociedad Espa?ola de Neumolog?a y Cirurg?a Tor?cica (SEPAR 1001/2010), Fondo de Investigaci?n Sanitaria (PS09/02457), Barcelona: Fondo de Investigaci?n Sanitaria (FIS PS09/00716), Galdakao: Fondo de Investigaci?n Sanitaria (FIS 09/01511), Huelva: Fondo de Investigaci?n Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud, Oviedo: Fondo de Investigaci?n Sanitaria (FIS PS09/03190), Sweden: All centers were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association, The Swedish Association against Lung and Heart Disease, Swedish Research Council for health, working life and welfare, G?teborg: also received further funding from the Swedish Council for Working Life and Social Research. Umea: also received funding from Vasterbotten Country Council ALF grant, Switzerland: The Swiss National Science Foundation (grants nos. 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, and 4026-028099), The Federal Office for Forest, Environment and Landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton's government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Z?rich, the Swiss Lung League, the canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais, and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, and UK: Medical Research Council (grant no.92091), support also provided by the National Institute for Health Research through the Primary Care Research Network., Financial support for ECRHS III: Australia: National Health and Medical Research Council, Estonia: Tartu: the Estonian Ministry of Education ( SF0180060s09 ), France: (All): Ministère de la Santé, Programme Hospitalier de Recherche Clinique national 2010, Bordeaux: INSERM U897 Université Bordeaux segalen, and Paris: Agence Nationale de la Santé, Région Ile de France, domaine d'intérêt majeur, Germany: Erfurt: German Research Foundation ( HE 3294/10-1 ), Hamburg: German Research Foundation ( MA 711/6-1 , NO 262/7-1 ), Iceland: Reykjavik: The Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation , California, USA , Orkuveita Reykjavikur (Geothermal plant), and Vegagerðin (The Icelandic Road Administration, Italy: All Italian centers were funded by the Italian Ministry of Health , Chiesi Farmaceutici SpA, in addition, Verona was funded by Cariverona Foundation and Education Ministry (Ministero dell'Istruzione, dell'Università e della Ricerca), Norway: Norwegian Research Council (grant no. 214123 ), Western Norway Regional Health Authorities (grant no. 911631 ), and Blond McIndoe Research Foundation, Spain: Fondo de Investigación Sanitaria (PS09/02457, PS09/00716, PS09/01511, PS09/02185, PS09/03190), Servicio Andaluz de Salud, Sociedad Española de Neumología y Cirurgía Torácica ( SEPAR 1001/2010), Fondo de Investigación Sanitaria (PS09/02457), Barcelona: Fondo de Investigación Sanitaria (FIS PS09/00716), Galdakao: Fondo de Investigación Sanitaria (FIS 09/01511), Huelva: Fondo de Investigación Sanitaria (FIS PS09/02185) and Servicio Andaluz de Salud, Oviedo: Fondo de Investigación Sanitaria (FIS PS09/03190), Sweden: All centers were funded by The Swedish Heart and Lung Foundation, The Swedish Asthma and Allergy Association , The Swedish Association against Lung and Heart Disease , Swedish Research Council for health, working life and welfare, Göteborg: also received further funding from the Swedish Council for Working Life and Social Research . Umea: also received funding from Vasterbotten Country Council ALF grant, Switzerland: The Swiss National Science Foundation (grants nos. 33CSCO-134276/1 , 33CSCO-108796 , 3247BO-104283 , 3247BO-104288 , 3247BO-104284 , 3247-065896 , 3100-059302 , 3200-052720 , 3200-042532 , and 4026-028099 ), The Federal Office for Forest, Environment and Landscape, The Federal Office of Public Health, The Federal Office of Roads and Transport, the canton's government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich, the Swiss Lung League , the canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais, and Zurich, SUVA, Freiwillige Akademische Gesellschaft , UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics , European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA, and UK: Medical Research Council (grant no. 92091 ), support also provided by the National Institute for Health Research through the Primary Care Research Network ., Conflicts of interest: D. S. Ferreira reports grants from the Asthma Foundation of Victoria , Allen and Hanburys , National Health and Medical Research Council . I. Pin reports travel grants and honoraria from Novartis , Zambon , and AstraZeneca , and nonfinancial support from AGIRàdom. R. Jõgi reports grants from Estonian Research Council Personal Research (grant no. 562 ), and consultancy, lecture, and travel fees from GlaxoSmithKline, Boehringer, and Novartis. The rest of the authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work., Financial support for ECRHS II: Australia: National Health and Medical Research Council, Belgium: Antwerp: Fund for Scientific Research (grant code G.0402.00 ), University of Antwerp , and Flemish Health Ministry, Estonia: Tartu: Estonian Science Foundation (grant no. 4350 ), France: (All) Programme Hospitalier de Recherche Clinique—Direction de la Recherche Clinique de Grenoble 2000 number 2610, Ministry of Health , Ministère de l’Emploi et de la Solidarité, Direction Génerale de la Santé, Centre Hospitalier Universitaire de Grenoble, Bordeaux: Institut Pneumologique d’Aquitaine, Grenoble: Comite des Maladies Respiratoires de l’Isere, Germany: Erfurt: GSF— National Research Centre for Environment and Health , Deutsche Forschungsgemeinschaft (grant code FR1526/1-1 ), Hamburg: GSF— National Research Centre for Environment and Health , Deutsche Forschungsgemeinschaft (grant code MA 711/4-1 ), Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Verona: Ministero dell’Università e della Ricerca Scientifica (MURST), Glaxo Wellcome s.p.a., Norway: Bergen: Norwegian Research Council , Norwegian Asthma and Allergy Association , Glaxo Wellcome AS , and Norway Research Fund, Spain: Fondo de Investigacion Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Hospital Universitario de Albacete, Consejeria de Sanidad, Barcelona: Sociedad Espanola de Neumología y Cirugía Toracica, Public Health Service (grant code R01 HL62633-01 ), Fondo de Investigaciones Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Consell Interdepartamentalde Recerca i Innovació Tecnológica (grant code 1999SGR 00241 ), Instituto de Salud Carlos III, Red de Centros de Epidemiología y Salud Pública, C03/09, Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176, Huelva: Fondo de Investigaciones Santarias (grant codes 97/0035-01 , 99/0034-01 , and 99/0034-02 ), Oviedo: Fondo de Investigaciones Sanitaria ( 97/0035-02 , 97/0035 , 99/0034-01 , 99/0034-02 , 99/0034-04 , 99/0034-06 , 99/350 , and 99/0034-07 ), European Commission ( EU-PEAL PL01237 ), Generalitat de Catalunya ( CIRIT 1999 SGR 00214), Hospital Universitario de Albacete, Sociedad Española de Neumología y Cirugía Torácica ( SEPAR R01 HL62633-01 ), Red de Centros de Epidemiología y Salud Pública (C03/09), Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias (C03/011), and Red de Grupos Infancia y Medio Ambiente (G03/176, Sweden: Göteborg, Umea, AND Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research , Swedish Asthma and Allergy Foundation , Swedish Cancer and Allergy Foundation , and Swedish Council for Working Life and Social Research ( FAS ), Switzerland: Basel: Swiss National Science Foundation , Swiss Federal Office for Education and Science , and Swiss National Accident Insurance Fund, UK: Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign)., Financial support for ECRHS I: The coordination of this work was supported by the European Commission , and the authors and participants are grateful to the late C. Baya and M. Hallen for their help during the study and K. Vuylsteek and the members of the COMAC for their support. The following grants helped to fund the local studies: Australia: Asthma Foundation of Victoria , Allen and Hanbury's, Belgium: Belgian Science Policy Office , National Fund for Scientific Research, Estonia: Estonian Science Foundation (grant no. 1088 ), France: Ministère de la Santé, Glaxo France , Institut Pneumologique d'Aquitaine , Contrat de Plan Etat-Région Languedoc-Rousillon , Caisse nationale de l'assurance maladie des travailleurs salariés, Comité national contre les maladies respiratoires et la tuberculose (90MR/10, 91AF/6), Ministre delegué de la santé, Réseau national de santé publique, France, Germany: Helmholtz Zentrum Munich and Bundesminister für Forschung und Technologie, Italy: Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Consiglio Nazionale delle Ricerche, Regione Veneto (grant RSF no. 381/05.93 ), Portugal: Glaxo Farmacêutica Lda, Sandoz Portugesa, Spain: Fondo de Investigación Sanitaria (nos. 91/0016-060-05/E , 92/0319 , and 93/0393 ), Hospital General de Albacete, Hospital General Juan Ramón Jiménez, Dirección Regional de Salud Pública (Consejería de Sanidad del Principado de Asturias), Consell Interdepartamental de Recerca i Innovació Tecnològica (1997 SGR 00079), and Servicio Andaluz de Salud, Sweden: The Swedish Medical Research Council , the Swedish Heart-Lung Foundation , the Swedish Association against Asthma and Allergy, Switzerland: Swiss National Science Foundation (grant no. 4026-28099 ), and UK: National Asthma Campaign , British Lung Foundation , Department of Health , South Thames Regional Health Authority ., The ALEC study is funded by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement number 633212. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. National funders who supported data collection in the original studies are listed in Appendix E4 in this article's Online Repository at www.jaci-inpractice.org . The funders had no role in the writing of the manuscript or the decision to submit it for publication., Commission of the European Communities, Medical Research Council (MRC), and Ageing Lungs European Cohorts ALEC
Subjects: Allergy, Epidemiology, Respiratory Medicine and Allergy, Cohort Studies, Atopy, Allergic sensitization, 0302 clinical medicine, Adrenal Cortex Hormones, Immunology and Allergy, Medicine, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Lung, Sensitization, Lungmedicin och allergi, biology, Inhaled corticosteroids, Lung function decline, Pyroglyphidae, Precision medicine, 3. Good health, PROPENSITY SCORE, medicine.anatomical_structure, IgE, Cohort study, Life Sciences & Biomedicine, Response to corticosteroids, Asthma, Adult, medicine.medical_specialty, Immunology, Allergic inflammation, 03 medical and health sciences, FEV1/FVC ratio, Internal medicine, Administration, Inhalation, Animals, Humans, House dust mite, Science & Technology, business.industry, Ageing Lungs in European Cohorts (ALEC) study, medicine.disease, biology.organism_classification, 030228 respiratory system, Cats, Human medicine, business
Abstract: BACKGROUND: Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment, but response to medication is variable. Patients with allergic inflammation generally show a better short-term response to ICSs; however, studies on predictors of long-term response are few. OBJECTIVE: To assess whether allergic sensitization can modify the association between ICS use and lung function decline over 20 years in adult asthma. METHODS: We used data from the 3 clinical examinations of the European Community Respiratory Health Survey. We measured ICS use (no use, and use for 8 years) and FEV1 decline among subjects with asthma over the 2 periods between consecutive examinations. We conducted a cohort study combining data of the 2 periods (906 observations from 745 subjects) to assess whether the association between ICS use and FEV1 decline was modified by allergic sensitization (IgE > 0.35 kU/L for any of house-dust mite, timothy grass, cat, or Cladosporium). RESULTS: FEV1 decline was similar for non-ICS users, as well as ICS users for less than 1.3 years, with and without allergic sensitization. However, among subjects on ICSs for a longer period, sensitization was associated with an attenuated decline (P-interaction = .006): in the group treated for more than 8 years, FEV1 decline was on average 27 mL/y (95% CIBonferroni-adjusted, 11-42) lower for subjects with sensitization compared with nonsensitized subjects. CONCLUSIONS: Our study suggests that biomarkers of atopy can predict a more favorable long-term response to ICSs. Randomized controlled studies are needed to confirm these findings. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Published: 2020
Full Text: View/download PDF

3. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort

Author: Amanda J. Cross, Petra H.M. Peeters, Pietro Ferrari, Françoise Clavel-Chapelon, Salvatore Panico, Augustin Scalbert, Anja Olsen, José María Huerta, Paolo Vineis, Gianluca Severi, Eva Ardanaz, H. Bas Bueno-de-Mesquita, Ruth C. Travis, Bénédicte Elena-Herrmann, Nicholas J. Wareham, Pagona Lagiou, Talita Duarte-Salles, Christina Bamia, Anne Tjønneland, Rudolf Kaaks, Bodil Ohlsson, Magdalena Stepien, Antonio Agudo, Krasimira Aleksandrova, Heiner Boeing, Isabelle Romieu, Kay-Tee Khaw, Veronika Fedirko, Domenico Palli, Julie A. Schmidt, Anne Fages, Rosario Tumino, Valeria Pala, Anna Floegel, Dimitrios Trichopoulos, Miren Dorronsoro, Marc J. Gunter, Klas Sjöberg, Clément Pontoizeau, Marie-Christine Boutron-Ruault, Elisabete Weiderpass, Tilman Kühn, Elio Riboli, Mazda Jenab, Antonia Trichopoulou, Esther Molina-Montes, Fages, Anne, Duarte Salles, Talita, Stepien, Magdalena, Ferrari, Pietro, Fedirko, Veronika, Pontoizeau, Clément, Trichopoulou, Antonia, Aleksandrova, Krasimira, Tjønneland, Anne, Olsen, Anja, Clavel Chapelon, Françoise, Boutron Ruault, Marie Christine, Severi, Gianluca, Kaaks, Rudolf, Kuhn, Tilman, Floegel, Anna, Boeing, Heiner, Lagiou, Pagona, Bamia, Christina, Trichopoulos, Dimitrio, Palli, Domenico, Pala, Valeria, Panico, Salvatore, Tumino, Rosario, Vineis, Paolo, Bueno de Mesquita, H. Ba, Peeters, Petra H, Weiderpass, Elisabete, Agudo, Antonio, Molina Montes, Esther, Huerta, José María, Ardanaz, Eva, Dorronsoro, Miren, Sjöberg, Kla, Ohlsson, Bodil, Khaw, Kay Tee, Wareham, Nick, Travis, Ruth C, Schmidt, Julie A, Cross, Amanda, Gunter, Marc, Riboli, Elio, Scalbert, Augustin, Romieu, Isabelle, Elena Herrmann, Benedicte, Jenab, Mazda, ISA NMR Methods for Metabolism - Methodes RMN en métabolomique (2014-2018), Institut des Sciences Analytiques (ISA), Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), ISA - Centre de RMN à très hauts champs, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), parent, International Agency for Cancer Research (IACR), Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens], Department of Epidemiology, Deutsches Institut für Ernahrungsforschung Potsdam-Rehbrücke (DIFE), Institute of Cancer Epidemiology, Danish Cancer Society, Department of Food Science [Copenhagen] (UCPH FOOD), Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Human Genetics Foundation (HuGeF), Università degli studi di Torino (UNITO), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Thermo Fisher Scientific, Thermo Fisher Scientific Inc., German Institute of Human Nutrition Potsdam-Rehbruecke, German Institute of Human Nutrition, Harvard School of Public Health, WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Nutritional Epidemiology Unit, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)-IRCCS Foundation, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Cancer Registry and Histopathology Unit, Civile - M.P.Arezzo Hospital, Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Julius Center for Health Sciences and Primary Care, VU University Medical Center [Amsterdam], Imperial College London-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Department of Community Medicine, University of Tromsø (UiT), Department of Research, Cancer Registry of Norway-Samfundet Folkhälsan, Helsinki, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet [Stockholm], Institut Català d'Oncologia, Spain Institute of Oncology, Andalusian School of Public Health [Granada], Consortium for Biomedical Research in Epidemiology and Public Health, CIBER de Epidemiología y Salud Pública (CIBERESP), Danish Cancer Society Research Center, Murcia Regional Health Council, Sección de Epidemiología de Enfermedades No Transmisibles, Navarre Public Health Institute, Epidemiology and Health Information, Public Health Department of Gipuzkoa, Volvo, VOLVO-VOLVO, Skane University Hospital [Lund], University of Cambridge School of Clinical Medicine, MRC epidemiology Unit, Addenbrooke's Hospital, Cancer Epidemiology Unit, University of Oxford [Oxford], Laboratoire d'informatique Fondamentale de Marseille (LIF), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Department of Chemistry, University of Cambridge [UK] (CAM), Nutrition and Metabolism Section, Biomarkers Group, Nutrition and Metabolism Section, This work was supported by the French National Cancer Institute (L'Institut National du Cancer, INCA, grant number 2009-139, PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, and Institut National de la Sante et de la Recherche Medicale (INSERM) (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands), European Research Council (ERC, grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skane and Vasterbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication., Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Centre Européen de Résonance Magnétique Nucléaire à Très Hauts Champs (CERMNTHC), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 'Civile M. P. Arezzo' Hospital, Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), [Fages,A, Pontoizeau,C, Elena-Herrmann,B] Institut des Sciences Analytiques, Centre de RMN à très hauts champs, CNRS/ENS Lyon/UCB Lyon-1, Université de Lyon, Villeurbanne, France. [Duarte-Salles,T, Stepien,M, Ferrari,P, Scalbert,A, Romieu,I, Jenab,M] International Agency for Research on Cancer (IARC-WHO), Lyon, France. [Fedirko,V] Department of Epidemiology, Rollins School of Public Health, Winship Cancer Institute, Emory University, Atlanta, USA. [Trichopoulou,A] Hellenic Health Foundation, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Aleksandrova,K, Floegel,A, Boeing,H] Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Clavel-Chapelon,F, Boutron-Ruault,M] INSERM, Centre for Research in Epidemiology and Population Health (CESP), nutrition, Hormones and Women’s Health Team, Villejuif, France. Université Paris Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France. [Severi,G, Vineis,P] Human Genetics Foundation (HuGeF), Torino, Italy. [Kaaks,R, Kuhn,T] Department of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany. [Lagiou,P, Bamia,C] Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece. [Lagiou,P, Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, USA. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy. [Pala,V] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Panico,S] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.P. Arezzo' Hospital, Ragusa, Italy. [Vineis,P, Peeters,PH] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Bueno-de-Mesquita,HB, Cross,A, Gunter,M, RibolI,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Peeters,PH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. [Weiderpass,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Samfundet Folkhälsan, Helsinki, Finland. [Agudo,A] Unit of Nutrition and Cancer, IDIBELL, Catalan Institute of Oncology-ICO, L’Hospitalet de Llobregat, Barcelona, Spain. [Molina-Montes,E] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Molina-Montes,E, Huerta,JM, Ardanaz, E] CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarre Public Health Institute, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Sjöberg,K] Department of Clinical Sciences, Lund University, Malmö, Sweden. Department of Gastroenterology and Nutrition, Skåne University Hospital, Malmö, Sweden. [Ohlsson,B] Department of Clinical Sciences, Division of Internal Medicine, Skåne University Hospital, Lund University, Malmö, Sweden. [Khaw,K] University of Cambridge School of Clinical Medicine, Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, UK. [Wareham,N] MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. [Travis,RC, Schmidt,JA] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., This work was supported by the French National Cancer Institute (L’Institut National du Cancer, Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication, Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Torino = University of Turin (UNITO), University of Naples Federico II = Università degli studi di Napoli Federico II, and University of Oxford
Subjects: Oncology, Male, Neoplasias Hepáticas, Cirrhosis, Magnetic Resonance Spectroscopy, Epidemiology, Hepatocellular carcinoma, Nuclear magnetic resonance, Cohort Studies, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Hepatocellular [Medical Subject Headings], 0302 clinical medicine, Risk Factors, Prospective Studies, Prospective cohort study, CIRRHOSIS, Early Detection of Cancer, Medicine(all), 0303 health sciences, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings], Liver Neoplasms, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings], Metabolómica, Estudios Prospectivos, General Medicine, Middle Aged, CANCER, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Liver Neoplasm, 030220 oncology & carcinogenesis, Female, Liver cancer, Case-Control Studie, Life Sciences & Biomedicine, Metabolomics, Carcinoma Hepatocelular, Research Article, Human, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], TISSUE METABOLOMICS, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings], Metabolomic, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [Medical Subject Headings], Càncer de fetge, 03 medical and health sciences, Medicine, General & Internal, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, IDENTIFY SERUM BIOMARKERS, Internal medicine, General & Internal Medicine, medicine, Humans, Obesity, Epidemiologia, 030304 developmental biology, FATTY LIVER-DISEASE, Aged, Hepatitis, Science & Technology, business.industry, Case-control study, METABONOMICS, Cancer, MASS-SPECTROMETRY, medicine.disease, NMR, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Prospective Studie, Case-Control Studies, DISCOVERY, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Drinking Behavior::Alcohol Drinking [Medical Subject Headings], Immunology, RISK-FACTORS, Cohort Studie, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, is difficult to diagnose and has limited treatment options with a low survival rate. Aside from a few key risk factors, such as hepatitis, high alcohol consumption, smoking, obesity, and diabetes, there is incomplete etiologic understanding of the disease and little progress in identification of early risk biomarkers. Methods: To address these aspects, an untargeted nuclear magnetic resonance metabolomic approach was applied to pre-diagnostic serum samples obtained from first incident, primary HCC cases (n = 114) and matched controls (n = 222) identified from amongst the participants of a large European prospective cohort. Results: A metabolic pattern associated with HCC risk comprised of perturbations in fatty acid oxidation and amino acid, lipid, and carbohydrate metabolism was observed. Sixteen metabolites of either endogenous or exogenous origin were found to be significantly associated with HCC risk. The influence of hepatitis infection and potential liver damage was assessed, and further analyses were made to distinguish patterns of early or later diagnosis. Conclusion: Our results show clear metabolic alterations from early stages of HCC development with application for better etiologic understanding, prevention, and early detection of this increasingly common cancer., This work was supported by the French National Cancer Institute (L’Institut National du Cancer; INCA; grant number 2009-139; PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); European Research Council (ERC; grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden); Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK).
Published: 2015
Full Text: View/download PDF

4. Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy

Author: Andrew S. Levey, Armando Teixeira-Pinto, Samuel Fung, Nicole Scholes-Robertson, Gloria Ashuntantang, Laura Cortés Sanabria, Samaya Anumudu, Amelie Bernier-Jean, Martin Howell, Louese Dunn, Tim Usherwood, Eduardo Lorca, Martin Wilkie, Andrea Matus Gonzalez, Magdalena Madero, Ikechi G. Okpechi, Daniel Gallego, Jonathan C. Craig, Adeera Levin, Allison Tong, Patrick Rossignol, Katherine Widders, Yeoungjee Cho, Ian H. de Boer, Andrea K. Viecelli, David C. Wheeler, Nicole Evangelidis, Bénédicte Sautenet, Laura Sola, Chandana Guha, The University of Sydney, Westmead Hospital [Sydney], MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Instituto Nacional de Cardiologia Ignacio Chavez, Université de Yaoundé I, Hospital Universitario de Guadalajara, Department of Medicine, Kidney Research Institute, University of Washington, Kidney Research Institute [Seattle] (KRI), Princess Margaret Hospital, Hong Kong, Federacion Nacional ALCER (Spanish Kidney Patient's Federation), Tufts University School of Medicine [Boston], University of British Columbia (UBC), Hospital Salvador, University of Cape Town, University of Alberta, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Dialysis Unit, CASMU-IAMPP, Montevideo, University of New South Wales [Sydney] (UNSW), Centre for Nephrology, UCL Medical School, Translational Research Institute, University College of London [London] (UCL), University of Queensland [Brisbane], Princess Alexandra Hospital, Brisbane, Baylor College of Medecine, Sheffield Children's NHS Foundation Trust, Flinders University [Adelaide, Australia], This project is supported by the National Health and Medical Research Council (NHMRC) Program Grant 1092597. NE is supported by the National Health and Medical Research Council (NHMRC) Program Grant 1092597. AT is supported by The University of Sydney Robinson Fellowship. YC is supported by the NHMRC Early Career Fellowship 1126256. AV is supported by a Jacquot Research Establishment Fellowship. The funding bodies do not have a role in the design, collection, analysis, and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication., Division of Nephrology and Hypertension, Faculty of Health Sciences, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours, and BOZEC, Erwan
Subjects: Nephrology, Medicine (General), Delphi Technique, 030232 urology & nephrology, Medicine (miscellaneous), urologic and male genital diseases, MESH: Delphi Technique, law.invention, Study Protocol, Clinical trials, 0302 clinical medicine, Randomized controlled trial, law, Chronic kidney disease, Outcome Assessment, Health Care, Pharmacology (medical), 030212 general & internal medicine, MESH: Treatment Outcome, MESH: Research Design, MESH: Nephrology, female genital diseases and pregnancy complications, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Renal Replacement Therapy, Treatment Outcome, Research Design, Outcomes research, Adult, medicine.medical_specialty, MESH: Renal Insufficiency, Chronic, 03 medical and health sciences, R5-920, Quality of life (healthcare), [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, Renal Insufficiency, Chronic, MESH: Outcome Assessment, Health Care, Intensive care medicine, MESH: Humans, business.industry, Core outcome set, MESH: Quality of Life, MESH: Adult, medicine.disease, Transplantation, Clinical trial, Quality of Life, MESH: Renal Replacement Therapy, Patient-centred outcomes, MESH: Systematic Reviews as Topic, business, Systematic Reviews as Topic, Kidney disease, Qualitative research
Abstract: Background Globally, over 1.2 million people die from chronic kidney disease (CKD) every year. Patients with CKD are up to 10 times more likely to die prematurely than progress to kidney failure requiring kidney replacement therapy. The burden of symptoms and impaired quality of life in CKD may be compounded by comorbidities and treatment side effects. However, patient-important outcomes remain inconsistently and infrequently reported in trials in patients with CKD, which can limit evidence-informed decision-making. The Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD) aims to establish a consensus-based core outcome set for trials in patients with CKD not yet requiring kidney replacement therapy to ensure outcomes of relevance to patients, caregivers and health professionals are consistently reported in trials. Methods SONG-CKD involves four phases: a systematic review to identify outcomes (domains and measures) that have been reported in randomised controlled trials involving adults with CKD who do not require kidney replacement therapy; stakeholder key informant interviews with health professionals involved in the care of adults with CKD to ascertain their views on establishing core outcomes in CKD; an international two-round online Delphi survey with patients, caregivers, clinicians, researchers, policy makers and industry representatives to obtain consensus on critically important outcome domains; and stakeholder consensus workshops to review and finalise the set of core outcome domains for trials in CKD. Discussion Establishing a core outcome set to be reported in trials in patients with CKD will enhance the relevance, transparency and impact of research to improve the lives of people with CKD. Trial registration Not applicable. This study is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/Studies/Details/1653.
Published: 2021
Full Text: View/download PDF

5. Assessing Prevalence and Factors Related to Frailty in Community-Dwelling Older Adults: A Multinomial Logistic Analysis

Author: Maria Rosa García-Merino, Encarnación Blanco-Reina, Gabriel Ariza-Zafra, Jenifer Valdellós, Inmaculada Bellido-Estevez, Lorena Aguilar-Cano, Ricardo Ocaña-Riola, [Blanco-Reina,E, Bellido-Estévez,I] Pharmacology and Therapeutics Department, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, Málaga, Spain. [Aguilar-Cano,L] Physical Medicine and Rehabilitation Department, Hospital Regional Universitario, Málaga, Spain. [García-Merino,MR, Valdellós,J] Health District of Málaga-Guadalhorce, Málaga, Spain. [Ocaña-Riola,R] Escuela Andaluza de Salud Pública, Granada, Spain. [Ocaña-Riola,R] Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. [Ariza-Zafra,G] Geriatrics Department, Complejo Hospitalario Universitario, Albacete, Spain., This research was funded by the Fundación Pública Andaluza Progreso y Salud, Consejería de Salud, Junta de Andalucía, through the Programme Proyectos de Investigación Biomédica (Grant number PI 0234/14). The APC was funded by the University of Málaga. The funders had no role in the design of the study, in the collection, analyses or interpretation of data, and in the writing of the manuscript or in the decision to publish the results.
Subjects: Gerontology, Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings], Activities of daily living, Persons::Persons::Age Groups::Adult::Aged::Frail Elderly [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Polypharmacy [Medical Subject Headings], Psychiatry and Psychology::Mental Disorders [Medical Subject Headings], Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Osteoarthritis [Medical Subject Headings], frailty, osteoarticular pathology, Article, primary care, Pharmacotherapy, Atención primaria de salud, Intervention (counseling), Medicine, older adults, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Polypharmacy, Anthropology, Education, Sociology and Social Phenomena::Human Activities::Activities of Daily Living [Medical Subject Headings], business.industry, Stressor, Anthropology, Education, Sociology and Social Phenomena::Human Activities::Activities of Daily Living::Independent Living [Medical Subject Headings], General Medicine, Psicopatología, psychopathology, Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings], Polimedicación, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings], Fragilidad, Artropatías, Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings], Logistic analysis, Multinomial distribution, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings], business, polymedication, Personas mayores frágiles, Psychopathology
Abstract: Frailty is an age-related clinical condition that typically involves a deterioration in the physiological capacity of various organ systems and heightens the patient’s susceptibility to stressors. For this reason, one of the main research goals currently being addressed is that of characterising the impact of frailty in different settings. The main aim of this study is to determine the prevalence of Fried’s frailty phenotype among community-dwelling older people and to analyse the factors associated with frailty. In this research study, 582 persons aged 65 years or more participated in this cross-sectional study that was conducted at primary healthcare centres in Málaga, Spain. Sociodemographic, clinical, functional and comprehensive drug therapy data were compiled. The relationship between the independent variables and the different states of frailty was analysed by using a multinomial logistic regression model. Frailty was present in 24.1% of the study sample (95% CI = 20.7–27.6) of whom 54.3% were found to be pre-frail and 21.6% were non-frail. The study variable most strongly associated with frailty was the female gender (OR = 20.54, 95% CI = 9.10–46.3). Other factors found to be associated with the state of frailty included age, dependence for the instrumental activities of daily living (IADL), polymedication, osteoarticular pathology and psychopathology. This study confirms the high prevalence of frailty among community-dwelling older people. Frailty may be associated with many factors. Some of these associated factors may be preventable or modifiable and, thus, provide clinically relevant targets for intervention. This is particularly the case for depressive symptoms, the clinical control of osteoarthritis and the use of polypharmacy.
Published: 2021

6. Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper

Author: Patrice Cacoub, Gilles Berrut, Olivier Hanon, Tahar Chouihed, Nicholas Lamblin, Nicholas Delarche, Emmanuel Andrès, Patrick Henry, Thibaud Damy, CHU Henri Mondor, Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Centre hospitalier de Pau, Pôle hospitalo-universitaire de gérontologie clinique [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'Immunologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, CHU Strasbourg, AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Université de Paris (UP), Novartis provided financial support for logistic management but was not involved in the writing of the manuscript., CHU Henri Mondor [Créteil], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Université Paris Cité (UPCité), and Gestionnaire, HAL Sorbonne Université 5
Subjects: medicine.medical_specialty, Hospital setting, Management of heart failure, Review, 030204 cardiovascular system & hematology, elderly, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Multidisciplinary approach, Community health care, medicine, Transitional care, 030212 general & internal medicine, Intensive care medicine, heart failure management, business.industry, General Medicine, medicine.disease, practical guidance, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Heart failure, Hospital admission, Medicine, Position paper, business
Abstract: International audience; Multidisciplinary management of worsening heart failure (HF) in the elderly improves survival. To ensure patients have access to adequate care, the current HF and French health authority guidelines advise establishing a clearly defined HF patient pathway. This pathway involves coordinating multiple disciplines to manage decompensating HF. Yet, recent registry data indicate that insufficient numbers of patients receive specialised cardiology care, which increases the risk of rehospitalisation and mortality. The patient pathway in France involves three key stages: presentation with decompensated HF, stabilisation within a hospital setting and transitional care back out into the community. In each of these three phases, HF diagnosis, severity and precipitating factors need to be promptly identified and managed. This is particularly pertinent in older, frail patients who may present with atypical symptoms or coexisting comorbidities and for whom geriatric evaluation may be needed or specific geriatric syndrome management implemented. In the transition phase, multi-professional post-discharge management must be coordinated with community health care professionals. When the patient is discharged, HF medication must be optimised, and patients educated about self-care and monitoring symptoms. This review provides practical guidance to clinicians managing worsening HF in the elderly.
Published: 2021
Full Text: View/download PDF

7. The role of organization of care in GPs' prevention practice

Author: Raphaëlle Delpech, Isabelle Pendola-Luchel, Pascaline Mourey, Mathilde Baumhauer, Arnaud Gautier, Henri Panjo, Rissane Ourabah, Lorraine Poncet, L. Rigal, Virginie Ringa, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, This project was funded by the French Research Institute in Public Health (IReSP). The funder had no role in the creation of the research question, design of the study, data collection, analysis, interpretation, or in the writing of this manuscript., Santé publique France - French National Public Health Agency [Saint-Maurice, France], Institut national d'études démographiques (INED), Université Paris-Saclay, and HAL UVSQ, Équipe
Subjects: Typology, medicine.medical_specialty, Attitude of Health Personnel, media_common.quotation_subject, [SDV]Life Sciences [q-bio], General Practice, MEDLINE, 03 medical and health sciences, 0302 clinical medicine, Negatively associated, General Practitioners, Surveys and Questionnaires, Health care, Medicine, Humans, 030212 general & internal medicine, Practice Patterns, Physicians', Care Planning, Socioeconomic status, media_common, 030505 public health, business.industry, Addiction, Public Health, Environmental and Occupational Health, Social environment, 3. Good health, [SDV] Life Sciences [q-bio], Family medicine, Global Positioning System, 0305 other medical science, business, Family Practice, Research Article
Abstract: Background: General practitioners (GPs) do not systematically include preventive recommendations in their practice, and some characteristics of health care organization are associated with more systematic prevention. But the characteristics of health care organization may act in a nonuniform manner depending on the type of preventive care. Thus, one characteristic can be positively associated with one type of preventive care and negatively associated with another. Our aim was to investigate the association between health care organization in general practice and different areas of preventive care (immunization and addiction prevention), in search of nonuniform associations. Methods: We used a representative survey of 1,813 French GPs conducted in 2009. Four preventive care practices were studied: immunization through flu and HPV vaccination, and prevention of addictive behaviors concerning tobacco and alcohol use. Characteristics of GPs’ health care organization and the social context of their practice were collected (spatial accessibility to GPs and socioeconomic level of the area of practice). We constructed mixed models to study associations and interactions between the organization variables and preventive care. Results: Four out of five characteristics of GPs’ organization have uneven impacts on different types of preventive care (p-interaction < 10-4). For example, number of daily consultations is associated with better immunization prevention but with poorer prevention counseling in addictive behaviors. In contrast, working with digital medical files is uniformly associated with both types of preventive care (OR = 1.29 [1.15–1.45]; P < 10-4). Conclusion: An approach centered on specific types of preventive care should help deepen our understanding of prevention and possibly help to identify a new typology for preventive care.
Published: 2021
Full Text: View/download PDF

8. Molecular Mimicry: a Paradigm of Host-Microbe Coevolution Illustrated by Legionella

Author: Silke Schmidt, Carmen Buchrieser, Sonia Mondino, Biologie des Bactéries intracellulaires - Biology of Intracellular Bacteria, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Collège doctoral [Sorbonne universités], Sorbonne Université (SU), Work in the C.B. laboratory is financed by the Institut Pasteur, and funding has been received from the French Government (grants ANR-10-LABX-62-IBEID and ANR-15-CE17-0014-03 to C.B.) and the Fondation de la Recherche Médicale (grant EQU201903007847 to C.B.). S.S. is a scholar in the Pasteur-Paris University (PPU) international Ph.D. program and received a stipend from the Institut Pasteur., S.M., S.S., and C.B. contributed to the conception and the design of the minireview. S.M. and S.S. researched and wrote the paper. C.B. directed and contributed to the writing of the manuscript., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-15-CE17-0014,ProgLegio,Biomarqueurs bactériens et humains d'intérêt pronostic pour les légionelloses sévères(2015), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Collège Doctoral
Subjects: Virulence Factors, Legionella, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Computational biology, medicine.disease_cause, Microbiology, Legionella pneumophila, Genome, Host-Microbe Biology, Biological Coevolution, 03 medical and health sciences, Bacterial Proteins, Virology, medicine, Humans, host-pathogen interactions, molecular mimicry, Gene, Coevolution, 030304 developmental biology, 0303 health sciences, Host Microbial Interactions, biology, 030306 microbiology, Host (biology), biology.organism_classification, eukaryotic-like proteins, QR1-502, Molecular mimicry, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, amoeba-resistant bacteria, Identification (biology), Minireview, Genome, Bacterial, Function (biology)
Abstract: Through coevolution with host cells, microorganisms have acquired mechanisms to avoid the detection by the host surveillance system and to use the cell’s supplies to establish themselves. Indeed, certain pathogens have evolved proteins that imitate specific eukaryotic cell proteins, allowing them to manipulate host pathways, a phenomenon termed molecular mimicry. Bacterial “eukaryotic-like proteins” are a remarkable example of molecular mimicry. They are defined as proteins that strongly resemble eukaryotic proteins or that carry domains that are predominantly present in eukaryotes and that are generally absent from prokaryotes., Through coevolution with host cells, microorganisms have acquired mechanisms to avoid the detection by the host surveillance system and to use the cell’s supplies to establish themselves. Indeed, certain pathogens have evolved proteins that imitate specific eukaryotic cell proteins, allowing them to manipulate host pathways, a phenomenon termed molecular mimicry. Bacterial “eukaryotic-like proteins” are a remarkable example of molecular mimicry. They are defined as proteins that strongly resemble eukaryotic proteins or that carry domains that are predominantly present in eukaryotes and that are generally absent from prokaryotes. The widest diversity of eukaryotic-like proteins known to date can be found in members of the bacterial genus Legionella, some of which cause a severe pneumonia in humans. The characterization of a number of these proteins shed light on their importance during infection. The subsequent identification of eukaryotic-like genes in the genomes of other amoeba-associated bacteria and bacterial symbionts suggested that eukaryotic-like proteins are a common means of bacterial evasion and communication, shaped by the continuous interactions between bacteria and their protozoan hosts. In this review, we discuss the concept of molecular mimicry using Legionella as an example and show that eukaryotic-like proteins effectively manipulate host cell pathways. The study of the function and evolution of such proteins is an exciting field of research that is leading us toward a better understanding of the complex world of bacterium-host interactions. Ultimately, this knowledge will teach us how host pathways are manipulated and how infections may possibly be tackled.
Published: 2020
Full Text: View/download PDF

9. Use of mental health supports by civilians exposed to the November 2015 terrorist attacks in Paris

Author: Stéphanie Vandentorren, Yvon Motreff, Maude Marillier, Gabrielle Rabet, Thierry Baubet, Cécile Vuillermoz, Lise Eilin Stene, Antoine Messiah, Philippe Pirard, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ministère des Affaires Sociales et de la Santé PIA ANR-10-EQPX-0021-01 Norges Forskningsråd: 288321, and This study was performed by Santé publique France as part of its remit. Santé publique France is funded by the French Ministry of Health. The ESPA 13 November survey is part of EQUIPEX Matrice’s '13 November' transdisciplinary research programme which is funded by the French General Secretariat for investment (SGPI) via the National Research Agency (ANR) and its 'Programme d’Investissement pour l’Avenir' (PIA ANR-10-EQPX-0021-01). PP, YM, GR, MM and SV are employees of Santé publique France. AM and TB are employees of the 'Institut National de la Santé et de la Recherche Médicale'. The contributions from LES and CV were funded by The Research Council of Norway (p.nr. 288321). The funding bodies had no role in the design of the study, data collection, data analysis, data interpretation or in the writing of the manuscript. Acknowledgments
Subjects: Adult, Male, medicine.medical_specialty, Paris, Referral, Health care use, Anxiety, Hospital Anxiety and Depression Scale, Health administration, Stress Disorders, Post-Traumatic, 03 medical and health sciences, 0302 clinical medicine, General Practitioners, Health service research, medicine, Humans, 030212 general & internal medicine, Psychiatry, Depression (differential diagnoses), Psychiatric Status Rating Scales, business.industry, Depression, lcsh:Public aspects of medicine, Health Policy, Public health, Post-traumatic, lcsh:RA1-1270, Middle Aged, Mental health, Stress disorders, Psychological first aid, Checklist, Mental health outreach, 3. Good health, 030227 psychiatry, Mental health services, Disaster medicine, Terrorist attacks, Female, Terrorism, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, medicine.symptom, business, Specialization, Research Article
Abstract: BackgroundThe use of mental health supports by populations exposed to terrorist attacks is rarely studied despite their need for psychotrauma care. This article focuses on civilians exposed to the November 2015 terrorist attacks in Paris and describes the different combinations of mental health supports (MHSu) used in the following year according to type of exposure and type of mental health disorder (MHD).MethodsSanté publique Franceconducted a web-based survey of civilians 8–11 months after their exposure to the November 2015 terrorist attacks in Paris. All 454 respondents met criterion A of the DSM-5 definition of post-traumatic stress disorder (PTSD). MHD (anxiety, depression, PTSD) were assessed using the PCL-5 checklist and the Hospital Anxiety and Depression Scale. MHSu provided were grouped under outreach psychological support, visits for psychological difficulties to a victims’ or victim support association, consultation with a general practitioner (GP), consultation with a psychiatrist or psychologist (specialist), and initiation of regular mental health treatment (RMHT). Chi-squared tests highlighted differences in MHSu use according to type of exposure (directly threatened, witnessed, indirectly exposed) and MHD. Phi coefficients and joint tabulations were employed to analyse combinations of MHSu use.ResultsTwo-thirds of respondents used MHSu in the months following the attacks. Visits to a specialist and RMHT were more frequent than visits to a GP (respectively, 39, 33, 17%). These were the three MHSu most frequently used among people with PTSD (46,46,23%), with depression (52,39,20%), or with both (56,58, 33%). Witnesses with PTSD were more likely not to have RMHT than those directly threatened (respectively, 65,35%). Outreach support (35%) and visiting an association (16%) were both associated with RMHT (Phi = 0.20 and 0.38, respectively). Very few (1%) respondents initiated RMHT directly. Those who indirectly initiated it (32%) had taken one or more intermediate steps. Visiting a specialist, not a GP, was the most frequent of these steps.ConclusionOur results highlight possibilities for greater coordination of mental health care after exposure to terrorist attacks including involving GP for screening and referral, and associations to promote targeted RMHT. They also indicate that greater efforts should be made to follow witnesses.
Published: 2020
Full Text: View/download PDF

10. Nocturia in patients with cognitive dysfunction: a systematic review of the literature

Author: Véronique Phé, Charles Joussain, Karel Everaert, Rebecca Haddad, Thomas F. Monaghan, G. Robain, Saskia Roggeman, Wendy Bower, Hôpital Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées (END-ICAP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine physique et réadaptation [CHU Raymond-Poincaré], Hôpital Raymond Poincaré [AP-HP], Sorbonne Université - Département de neurologie 2 - Mazarin, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), SociÃ©tÃ© FranÃ§aise de MÃ©decine Vasculaire, SFMV, and RH reports grants from, Fonds de dotation Renaitre, Société Française de Médecine Physique et de Réadaptation with the institutional support of Merz Pharma France and Société Interdisciplinaire Francophone d’UroDynamique et de Pelvi Périnéologie. Authors independently conceptualized the design, methods, data collection, analysis and writing of the manuscript and grants did not influence the content.
Subjects: medicine.medical_specialty, Epidemiology, IMPACT, medicine.medical_treatment, 030232 urology & nephrology, MEDLINE, lcsh:Geriatrics, urologic and male genital diseases, FREQUENCY, 03 medical and health sciences, 0302 clinical medicine, Cognitive dysfunction, Lower urinary tract symptoms, Medicine and Health Sciences, medicine, QUALITY, Nocturia, TERMINOLOGY, RISK, Rehabilitation, business.industry, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, MORTALITY, Confounding, Cognition, STANDARDIZATION, medicine.disease, SLEEP, female genital diseases and pregnancy complications, OVERACTIVE BLADDER, PREVALENCE, 3. Good health, lcsh:RC952-954.6, Systematic review, Geriatrics and Gerontology, medicine.symptom, business, 030217 neurology & neurosurgery, Research Article, Clinical psychology
Abstract: Background The objective of this study is to evaluate current literature on the association between cognitive dysfunction and nocturia. Methods A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was conducted through MEDLINE, EMBASE and COCHRANE databases and completed in November 2019. Randomized and non-randomized studies were included if they assessed the association between cognitive dysfunction and nocturia in older participants with or without neurological diseases. The quality of included studies was evaluated using the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS). Results A total of 8 cross-sectional studies conducted in older patient populations met the criteria for inclusion. A statistically significant association was identified in 6 studies on univariate analysis, which persisted in 2 studies after controlling for confounding factors. The association between cognitive dysfunction and nocturia was positive for all 6 significant analyses. The overall risk of bias was unclear. Conclusion A significant positive association between cognitive dysfunction and nocturia was identified. However, research has been limited to cross-sectional studies, which precludes identification of causality between cognitive dysfunction and nocturia. Heightened awareness of the complex interplay between cognition and nocturia would allow professionals involved in the care of cognitively impaired patients with concomitant nocturia to more effectively manage these symptoms.
Published: 2020
Full Text: View/download PDF

11. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial

Author: Marc Leone, Jacques Duranteau, Eric Vicaut, François Dépret, Daniel De Backer, Matthieu Legrand, Bruno Levy, Patrick Rossignol, Hafid Ait Oufella, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, Université Paris Diderot - Paris 7 (UPD7), Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), University of California [San Francisco] (UCSF), University of California, Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Interrégional Edith Cavell (CHIREC), Hôpitaux Universitaires Paris Sud, Hôpital Nord AP‐MM Marseille, France (AP‐MM Marseille), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Réanimation Médicale [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), The study is funded by a grant from the Programme Hospitalier de Recherche Clinique - PHRC National 2017 from the French Minister of Health. The funding body has no role in the design of the study, collection, analysis, and interpretation of the data, and writing of the manuscript., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), University of California [San Francisco] (UC San Francisco), University of California (UC), Service d'Anesthésie réanimation [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université libre de Bruxelles (ULB), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Assistance Publique - Hôpitaux de Marseille (APHM), Université de Lorraine (UL), and BOZEC, Erwan
Subjects: Inotrope, Resuscitation, Organ Dysfunction Scores, Vasodilator Agents, Medicine (miscellaneous), Cardiorespiratory Medicine and Haematology, Pharmacologie, Capillary refill time, law.invention, Prostacyclin, Study Protocol, 0302 clinical medicine, Randomized controlled trial, law, Vasodilator, Multicenter Studies as Topic, Pharmacology (medical), 030212 general & internal medicine, Prospective Studies, Infusions, Intravenous, Randomized Controlled Trials as Topic, Outcome, lcsh:R5-920, Shock, Hematology, Sciences bio-médicales et agricoles, Shock, Septic, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Phase III as Topic, Treatment Outcome, Anesthesia, 6.1 Pharmaceuticals, SOFA score, France, medicine.symptom, I-MICRO trial investigators, Intravenous, lcsh:Medicine (General), Infusions, Randomization, Clinical Trials and Supportive Activities, Clinical Sciences, Skin mottling, Sepsis, 03 medical and health sciences, Double-Blind Method, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Clinical Research, General & Internal Medicine, medicine, Humans, Clinical Trials, Iloprost, Septic shock, business.industry, Septic, Microcirculation, Organ dysfunction, Hemodynamics, Evaluation of treatments and therapeutic interventions, 030208 emergency & critical care medicine, medicine.disease, Clinical Trials, Phase III as Topic, Cardiovascular System & Hematology, business
Abstract: Background: Septic shock remains a significant cause of death in critically ill patients. During septic shock, some patients will retain microcirculatory disorders despite optimal hemodynamic support (i.e. fluid resuscitation, vasopressors, inotropes). Alterations in the microcirculation are a key pathophysiological factor of organ dysfunction and death in septic shock patients. Ilomedin is a prostacyclin analog with vasodilatory effect and anti-Thrombotic properties (i.e. inhibition of platelet aggregation) preferentially at the microcirculatory level. We hypothesize that early utilization of intravenous Ilomedin in septic shock patients with clinical persistence of microperfusion disorders would improve the recovery of organ dysfunction. Methods: The I-MICRO trial is a multicenter, prospective, randomized, double-blinded, placebo-controlled study. We plan to recruit 236 adult patients with septic shock and persistent microcirculatory disorders (i.e. skin mottling or increased capillary refill time) despite hemodynamic support. Participants will be randomized to receive a 48-h intravenous infusion of either Ilomedin or placebo starting at the earliest 6 h and later 24 h after septic shock. The primary outcome will be the change (delta) of sequential organ failure assessment (SOFA) score between randomization and day 7. Secondary outcomes will include mean SOFA score during the first 7 days after randomization, mortality at day 28 post-randomization, number of ventilation-free survival days in the 28 days post-randomization, number of renal replacement therapy-free survival days in the 28 days post-randomization, number of vasopressor-free survival days in the 28 days post-randomization, and mottling score at day 1 after randomization. Discussion: The trial aims to provide evidence on the efficacy and safety of Ilomedin in patients with septic shock and persistent microcirculatory disorders. Trial registration: NCT NCT03788837. Registered on 28 December 2018, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2020
Full Text: View/download PDF

12. Klebsiella pneumoniae carriage in low-income countries: antimicrobial resistance, genomic diversity and risk factors

Author: Jean-Marc Collard, Perlinot Herindrainy, Raymond Bercion, Didier Guillemot, Maria Pardos de la Gandara, Andriniaina Rakotondrasoa, Benoit Garin, Elisabeth Delarocque-Astagneau, Agathe de Lauzanne, Melanie Hennart, Sylvain Brisse, Carla Rodrigues, Virginie Passet, Thierno Abdoulaye Diallo, Muriel Vray, Bich-Tram Huynh, Alexandra Kerleguer, Laurence Borand, Abdoulaye Seck, Biostatistique, Biomathématique, Pharmacoépidémiologie et Maladies Infectieuses (B2PHI), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Biodiversité et Epidémiologie des Bactéries pathogènes - Biodiversity and Epidemiology of Bacterial Pathogens, Institut Pasteur [Paris], Unité de Bactériologie Expérimentale [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut Pasteur de Dakar, Réseau International des Instituts Pasteur (RIIP), Institut Pasteur du Cambodge, Institut Pasteur de Bangui, Centre National de Référence - National Reference Center Escherichia coli, Shigella et Salmonella (CNR-ESS), This work was supported by the Institut Pasteur programme Action Concertee Inter-Pasteurienne (Grant A-14-2014) and by the French government’s Investissement d’Avenir program Laboratoire d’Excellence ‘Integrative Biology of Emerging Infectious Diseases’ (grant ANR-10-LABX-62-IBEID). Support to the BIRDY project was provided by the Total Foundation, MSDAVENIR and the Monaco Department of International Cooperation. CR was supported financially by the MedVetKlebs project, a component of European Joint Programme One Health EJP, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 773830. The funders had no role in study design, data collection and analysis, interpretation, or writing of the manuscript., We thank all collaborators of the BIRDY program: Rasoanaivo Fanjalalaina Vololonirina, Andrianonimiadana Lova Maminirina, Rabearitiana Lydos, Rasoloson Dimitri, Randrianirina Frédérique, Ratsima Hariniaina Elisoa, Volahasina Antsa Tanjona, Volahasina Antso Fenitra, Randriamamonjiarison Aina Nirina, Andrianirina Zafitsara Zo, Andriatahina Todisoa, Vincent Richard, Awa Ndir, Amy Gassama Sow, Balla Sy, Marguerite Diatta, Pape Samba Dieye, Jean Baptiste Diouf, Joseph Faye, Abibatou Ndiaye, Bouya Ndao, Thida Chon, Veronique Ngo, Arnaud Tarantola, Sok Touch, Patrice Piola, Sophie Goyet, Siyin Lach, Elsa Kermorvant-Duchemin, Michael Padget, Laurence Watier, and Abdou Armya Youssouf. We thank all physicians, laboratory staff, field interviewers, and community workers involved in the project. We thank Leonardo Panunzi for assistance with genomic analyses of resistance genes, and the 'Plateforme de Microbiologie Mutualisée' of Institut Pasteur for genomic sequencing. We are grateful to all women participating in the BIRDY program., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 773830,H2020-SFS-2017-1,MedVetKlebs (a component of European Joint Programme One Health EJP)(2018), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP), European Project: 773830,H2020-SFS-2017-1,MedVetKlebs (a component of European Joint Programme One Health)(2018), Moulherat, Isabelle, Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID, and Klebsiella pneumoniae: from ecology to source attribution and transmission control - MedVetKlebs (a component of European Joint Programme One Health) - - H2020-SFS-2017-12018-01-01 - 2019-12-31 - 773830 - VALID
Subjects: 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, antibiotic resistance, Klebsiella pneumoniae, media_common.quotation_subject, Developing country, RC799-869, Biology, Microbiology, genomic diversity, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, low-income countries, medicine, media_common, carriage, 2. Zero hunger, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Public health, Gastroenterology, Diseases of the digestive system. Gastroenterology, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, Multiple drug resistance, 030104 developmental biology, Infectious Diseases, Carriage, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Research Paper/Report, community, 030211 gastroenterology & hepatology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Diversity (politics), Research Article
Abstract: The genomic sequencing data were deposited in the NCBI/ENA/DDBJ databases and are accessible via the BioProject PRJEB29143; International audience; Klebsiella pneumoniae (hereafter, Kp) is a major public health threat responsible for high levels of multidrug resistant (MDR) human infections. Besides, Kp also causes severe infections in the community, especially in Asia and Africa. Although most Kp infections are caused by endogenous intestinal carriage, little is known about the prevalence and microbiological characteristics of Kp in asymptomatic human carriage, and attached risk factors including environmental sources exposure. Here, 911 pregnant women from communities in Madagascar, Cambodia, and Senegal were screened for gut colonization by Kp. Characteristics of Kp strains (antimicrobial susceptibility, genomic diversity, virulence, and resistance genes) were defined, and associated risk factors were investigated.Kp carriage rate was 55.9%, and Kp populations were highly heterogeneous (6 phylogroups, 325 sequence types, Simpson index 99.6%). One third of Kp isolates had acquired antimicrobial resistance genes. MDR-Kp (11.7% to 39.7%) and extended spectrum beta-lactamase (ESBL)-producing Kp (0.7% to 14.7%) varied among countries. Isolates with virulence genes were detected (14.5%). Environmental exposure factors including food, animal contacts, or hospitalization of household members were associated with carriage of Kp, antimicrobial resistance and hypervirulence. However, risk factors were country-specific and Kp subpopulation-specific.This large-scale multicenter study uncovers the huge diversity of Kp in human gut carriage, demonstrates that antimicrobial resistance is widespread in communities of three low-income countries, and underlines the challenges posed by Kp colonization to the control of antimicrobial
Published: 2020
Full Text: View/download PDF

13. Adherence to the Mediterranean Lifestyle and Desired Body Weight Loss in a Mediterranean Adult Population with Overweight: A PREDIMED-Plus Study

Author: Josep A. Tur, Itziar Abete, José J. Gaforio, Jordi Salas-Salvadó, Nerea Becerra-Tomás, Francisco J. Tinahones, Albert Goday, Xavier Pintó, Maria Dolors Zomeño, Julia Wärnberg, Alejandro Oncina-Canovas, Carmen Saiz, Jessica Pérez-López, Dolores Corella, Clotilde Vázquez, Lucas Tojal-Sierra, Leyre Notario-Barandiaran, Marga Morey, Lidia Daimiel, Aurora Bueno-Cavanillas, José Manuel Santos-Lozano, José Lapetra, F. Javier Basterra-Gortari, Julia Muñoz, Alicia Julibert, Marian Martín, M. Rosa Bernal-Lopez, Sara Castro-Barquero, Ana Galera, Josep Vidal, Vicente Martín-Sánchez, Miguel Ruiz-Canela, Maria C Belló-Mora, Emilio Ros, Ignacio M. Gimenez-Alba, Antonio García Ríos, Tamara Casañas-Quintana, Ángel M. Alonso-Gómez, Jesús García-Gavilán, Josep Basora, Jesús Vioque, Ramon Estruch, Dora Romaguera, Luis Serra-Majem, Cesar I Fernandez-Lazaro, Pilar Matía-Martín, Escarlata Angullo-Martinez, Cristina Bouzas, Carmen Sayón-Orea, J. Alfredo Martínez, Olga Castañer, Maria del Mar Bibiloni, [Bouzas,C, Bibiloni,MM, Julibert,A, Ruiz-Canela,M, Salas-Salvadó,J, Corella,D, Zomeño,MD, Romaguera,D, Alonso-Gómez,ÁM, Wärnberg,J, Martínez,JA, Serra-Majem,L, Estruch,R, Tinahones,FJ, Lapetra,J, Pintó,X, García Ríos,A, Vázquez,C, Ros,E, Fernandez-Lázaro,CI, Becerra-Tomás,N, Gimenez-Alba,IM, Muñoz,J, Morey,M, Pérez-López,J, Abete,I, Casañas-Quintana,T, Castro-Barquero,S, Bernal-López,MR, Santos-Lozano,JM, Galera,A, Angullo-Martinez,E, Basterra-Gortari,FJ, Basora,J, Saiz,C, Castañer,O, Martín,M, Belló-Mora,MC, Sayón-Orea,C, García-Gavilán,J, Goday,A, Tur,JA] CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Bouzas,C, Tojal-Sierra,L, Tur,JA] Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Guillem Colom Bldg, Campus, Palma de Mallorca, Spain. [Bouzas,C, Tur,JA] Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. [Ruiz-Canela,M, Sayón-Orea,C] Department of Preventive Medicine and Public Health, IdISNA, University of Navarra, Pamplona, Spain. [Salas-Salvadó,J, García-Gavilán,J] Universitat Rovira i Virgili, Department of Biochemistry and Biotechnology, Human Nutrition Unit, Reus, Spain. [Salas-Salvadó,J] Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain. [Corella,D, Saiz,C] Department of Preventive Medicine, University of Valencia, Valencia, Spain. [Zomeño,MD, Goday,A] Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Mèdica (IMIM), Barcelona, Spain. [Zomeño,MD] Blanquerna School of Health Sciences, Universitat Ramon Llull, Barcelona, Spain. [Vioque,J, Oncina-Canovas,A, Notario-Barandiarán,L] Unit of Nutritional Epidemiology, Miguel Hernández University, ISABIAL-UMH, Alicante, Spain. [Vioque,J, Bueno-Cavanillas,A, Gaforio,JJ, Notario-Barandiarán,L] CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Alonso-Gómez,ÁM, Belló-Mora,MC] Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain. [Wärnberg,J, Pérez-López,J] Department of Nursing, School of Health Sciences, University of Málaga-IBIMA, Málaga, Spain. [Martínez,JA] Precision Nutrition Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. [Martínez,JA, Abete,I] Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain. [Serra-Majem,L, Casañas-Quintana,T] Institute for Biomedical Research, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain. [Estruch,R, Castro-Barquero,S] Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. [Tinahones,FJ, Bernal-López,MR] Virgen de la Victoria Hospital, Department of Endocrinology, Biomedical Research Institute of Málaga (IBIMA), University of Málaga, Málaga, Spain. [Lapetra,J, Santos-Lozano,JM] Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla, Spain. [Pintó,X, Galera,A] Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. [García Ríos,A] Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. [Bueno-Cavanillas,A] Department of Preventive Medicine, University of Granada, Granada, Spain. [Gaforio,JJ] Department of Health Sciences, Centro de Estudios Avanzados en Olivar y Aceites de Oliva, University of Jaen, Jaen, Spain. [Matía-Martín,P] Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Daimiel,L] Nutritional Genomics and Epigenomics Group, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. [Martín-Sánchez,V] CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Martín-Sánchez,V] Institute of Biomedicine (IBIOMED), University of León, León, Spain. [Vidal,J] Department of Endocrinology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. [Vázquez,C] Department of Endocrinology, Fundación Jiménez-Díaz, Madrid, Spain. [Ros,E] Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain. [Angullo-Martinez,E] Escola Graduada Primary Health Care Center, IBSalut, Palma de Mallorca, Spain. [Basterra-Gortari,FJ, Sayón-Orea,C] Servicio Navarro de Salud, Osasunbidea, Pamplona, Spain., The PREDIMED-Plus trial was supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (five coordinated FIS projects led by J.S.-S. and J.Vidal, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, and PI19/01332, the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant to J.S.-S., the European Research Council (Advanced Research Grant 2013–2018, 340918) to Miguel Ángel Martínez-González, the Recercaixa Grant to J.S.-S. (2013ACUP00194), Grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013, PS0358/2016, and PI0137/2018), a Grant from the Generalitat Valenciana (PROMETEO/2017/017), a SEMERGEN Grant, EU-COST Action CA16112, a Grant of support to research groups no. 35/2011 from the Balearic Islands Government, Grants from Balearic Islands Health Research Institute (IDISBA), funds from the European Regional Development Fund (CIBEROBN CB06/03 and CB12/03) and from the European Commission (EAT2BENICE_H2020_SFS2016). M. Rosa Bernal-López was supported by 'Miguel Servet Type I' program (CP15/00028) from the ISCIII-Madrid (Spain), cofinanced by the European Regional Development Fund. Jordi Salas-Salvadó is partially supported by ICREA under the ICREA Academia programme. Cristina Bouzas received a Fernando Tarongí Bauzà PhD Grant. I.M Gimenez-Alba received a grant FPU from the Ministry of Science, Innovation and Univesities (reference FPU 18/01703). The funding sponsors had no role in the design of the study, in the collection, analyses, or interpretation of the data, and in the writing of the manuscript, and in the decision to publish the results.
Subjects: Male, Mediterranean diet, Obesidad, ejercicio físico, Body Mass Index, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Medicine, mediana edad, education.field_of_study, anciano, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Age Factors [Medical Subject Headings], dieta, protocolos de quimioterapia antineoplásica combinada, 3. Good health, Older adults, metotrexato, programas de reducción de peso, Obesitat, lcsh:Nutrition. Foods and food supply, Personas mayores frágiles, Ideal weight, Lifestyles, Check Tags::Male [Medical Subject Headings], lcsh:TX341-641, Article, Estilo de vida, 03 medical and health sciences, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight [Medical Subject Headings], Anthropology, Education, Sociology and Social Phenomena::Human Activities::Exercise [Medical Subject Headings], ifosfamida, Humans, cisplatino, Ifosfamide, education, Exercise, Aged, conducta alimentaria, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome X [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Life Style [Medical Subject Headings], PREDIMED-Plus, medicine.disease, Obesity, Methotrexate, Check Tags::Female [Medical Subject Headings], Desired weight loss, Metabolic syndrome, Cisplatin, Body mass index, Demography, obesity, cumplimiento del paciente, humanos, Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], Ideal Body Weight, desired weight loss, Health Care::Health Care Facilities, Manpower, and Services::Health Promotion::Weight Reduction Programs [Medical Subject Headings], Overweight, Diet, Mediterranean, Mediterranean lifestyle, Health Care::Health Care Facilities, Manpower, and Services::Health Services::Preventive Health Services::Health Promotion::Healthy People Programs [Medical Subject Headings], Weight loss, 030212 general & internal medicine, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Health Behavior::Patient Compliance [Medical Subject Headings], Abdominal obesity, older adults, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], 2. Zero hunger, Nutrition and Dietetics, mediterranean lifestyle, sobrepeso, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet, Mediterranean [Medical Subject Headings], Age Factors, ideal weight, Middle Aged, Peso corporal ideal, Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Ideal Body Weight [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings], Weight Reduction Programs, Body image, Female, medicine.symptom, peso corporal ideal, Estils de vida, doxorrubicina, body image, Population, Imagen corporal, 030209 endocrinology & metabolism, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Feeding Behavior [Medical Subject Headings], overweight, Healthy Lifestyle, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], business.industry, índice de masa corporal, Feeding Behavior, Dieta mediterránea, Diet, Doxorubicin, Sobrepeso, Patient Compliance, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Perception::Body Image [Medical Subject Headings], business, Food Science
Abstract: Background. Body weight dissatisfaction is a hindrance to following a healthy lifestyle and it has been associated with weight concerns. Objectives. The aim of this study was to assess the association between the adherence to the Mediterranean lifestyle (diet and exercise) and the desired body weight loss in an adult Mediterranean population with overweight. Methods. Cross-sectional analysis in 6355 participants (3268 men; 3087 women) with metabolic syndrome and BMI (Body mass index) between 27.0 and 40.0 kg/m2 (55–75 years old) from the PREDIMED-Plus trial. Desired weight loss was the percentage of weight that participants wished to lose. It was categorized into four cut-offs of this percentage (Q1, European Research Council (ERC) 340918, Recercaixa Grant 2013ACUP00194, Junta de Andalucia PI0458/2013 PS0358/2016 PI0137/2018, Generalitat Valenciana PROMETEO/2017/017, SEMERGEN Grant, European Union (EU) European Cooperation in Science and Technology (COST) CA16112, Balearic Islands Government 35/2011, Balearic Islands Health Research Institute (IDISBA), European Union (EU) CIBEROBN CB06/03 CB12/03 PI13/00673 PI13/00492 PI13/00272 PI13/01123 PI13/00462 PI13/00233 PI13/02184 PI13/00728 PI13/01090 PI13/01056, European Commission Joint Research Centre EAT2BENICE_H2020_SFS2016, "Miguel Servet Type I" program from the ISCIII-Madrid (Spain) CP15/00028, ICREA under the ICREA Academia programme, Fernando Tarongi Bauza PhD Grant, FPU from the Ministry of Science, Innovation and Univesities FPU 18/01703, Spanish government, ISCIII, through the Fondo de Investigacion para la Salud (FIS), Especial Action Project entitled: Implementacion y evaluacion de una intervencion intensiva sobre la actividad fisica Cohorte PREDIMED-Plus grant, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332
Published: 2020

14. Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis

Author: Gaelle Dzangue-Tchoupou, Olivier Vittecoq, Céline Derambure, Maria Antonietta D'Agostino, Thierry Lequerré, Bodescot, Myriam, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), The APPRAISE trial was funded by Bristol-Myers Squibb and this ancillary study was funded by Bristol-Myers Squibb which was involved in the design of the study as well as in the collection of clinical data and biological samples, in the interpretation of data, in the writing of this manuscript and in the decision to submit the manuscript for publication. This does not alter our adherence to PLOS ONE policies on sharing data and materials., and Hôpital Charles Nicolle [Rouen]-CHU Rouen
Subjects: Male, 0301 basic medicine, Oncology, Cell signaling, Settore MED/16 - REUMATOLOGIA, Gene Expression, Arthritis, Apoptosis, Signal transduction, medicine.disease_cause, Biochemistry, Autoimmunity, Arthritis, Rheumatoid, White Blood Cells, 0302 clinical medicine, Animal Cells, Rheumatoid, Medicine and Health Sciences, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Multidisciplinary, TCR signaling cascade, Cell Death, T Cells, Signaling cascades, CD28, Middle Aged, C-Reactive Proteins, medicine.anatomical_structure, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Cell Processes, Antirheumatic Agents, Rheumatoid arthritis, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Medicine, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Female, Cellular Types, Research Article, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Science, Immune Cells, T cell, Immunology, Motor Proteins, Cytotoxic T cells, Rheumatoid Arthritis, Autoimmune Diseases, Abatacept, 03 medical and health sciences, Rheumatology, Molecular Motors, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Genetics, medicine, Humans, 030203 arthritis & rheumatology, Blood Cells, business.industry, Biology and Life Sciences, Proteins, Cell Biology, medicine.disease, Methotrexate, 030104 developmental biology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Clinical Immunology, Clinical Medicine, Transcriptome, business, CD80
Abstract: International audience; Objectives: Abatacept acts as a competitive inhibitor of the CD28/(CD80/86) costimulation signal required for T cell activation. Mechanisms of action of abatacept have not been fully investigated. The objective of this study was to provide detailed insight into the mode of action of Abatacept based on gene expression data. Methods: In this ancillary study from the APPRAISE trial, we investigated the global molecular effects of Abatacept in whole blood samples collected prospectively in biologic naive rheumatoid arthritis patients (n = 19) at baseline and 6 months after the initiation of Abatacept therapy concomitant with methotrexate. Whole human genome microarrays (4x44K) were performed on both baseline and 6-month samples from responders and non-responders patients categorized according to EULAR criteria. T-test with Benjamini-Hochberg correction was performed to identify significant gene expression changes. Gene Ontology and Single Experiment Analysis tools allowed us to highlight specific biological mechanisms involved in methotrexate/Abatacept. Results: In methotrexate/Abatacept responders, 672 genes were significantly (q
Published: 2020
Full Text: View/download PDF

15. The effect of an online exercise programme on bone health in paediatric cancer survivors (iBoneFIT): study protocol of a multi-centre randomized controlled trial

Author: Francisco Jesus Llorente-Cantarero, Manuel Arroyo-Morales, Maria C. Vicho-González, Maria J. Ortega-Acosta, Francisco B. Ortega, Luis Gracia-Marco, Dimitris Vlachopoulos, Vicente Martínez-Vizcaíno, Ana I. Benito-Bernal, Manuel Muñoz-Torres, Esther Ubago-Guisado, Idoia Labayen, Jonatan R. Ruiz, Juan F. Pascual-Gázquez, Maria Elena Mateos, Maria J. Sánchez, Jose J. Gil-Cosano, Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa. ISFOOD - Institute for Innovation and Sustainable Development in Food Chain, Universidad Pública de Navarra. Departamento de Ciencias de la Salud, Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila, [Gil-Cosano,JJ, Ubago-Guisado,E, Ortega,FB, Ruiz,JR, Gracia-Marco,L] PROFITH 'PROmoting FITness and Health through Physical Activity' Research Group, Sport and Health University Research Institute (iMUDS), Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain. [Sánchez,MJ] Andalusian School of Health (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria Ibs.GRANADA, Granada, Spain. [Sánchez,MJ] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Sánchez,MJ] Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain. [Ortega-Acosta,MJ, Pascual-Gázquez,JF] Servicio de Pediatría y Oncohematología Pediátricas, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Mateos,ME, Vicho-González,MC] Pediatric Oncology Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain. [Mateos,ME, Llorente-Cantarero,FJ] Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Córdoba, Spain. [Benito-Bernal,AI] Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Llorente-Cantarero,FJ] CIBEROBN, (Physiopathology of Obesity and Nutrition) Institute of Health Carlos III (ISCIII), Madrid, Spain. [Llorente-Cantarero,FJ] Department of Specific Didactics, Faculty of Education, University of Córdoba, Córdoba, Spain. [Labayen,I] Institute for Innovation and Sustainable Development in Food Chain (IS-FOOD), Navarra’s Health Research Institute (IdiSNA), Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain. [Martinez-Vizcaino,V] Universidad de Castilla-La Mancha, Health and Social Research Center, Cuenca, Spain. [Martinez-Vizcaino,V] Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile. [Vlachopoulos,D] Children’s Health and Exercise Research Centre, Sport and Health Sciences, University of Exeter, Exeter, UK. [Arroyo-Morales, M] Biohealth Research Institute in Granada (ibs.GRANADA), Granada, Spain. [Arroyo-Morales, M] Department of Physiotherapy, University of Granada, Granada, Spain. [Arroyo-Morales, M] 'Cuídate' Support Unit for Oncology Patients (UAPO), Sport and Health University Research Institute (iMUDS), Granada, Spain. [Muñoz-Torres,M] Bone Metabolic Unit, Endocrinology and Nutrition Division, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Granada, Spain. [Muñoz-Torres,M] CIBERFES, Instituto de Salud Carlos III, Madrid, Spain. [Muñoz-Torres,M] Department of Medicine, Universidad de Granada, Granada, Spain., The iBoneFIT project is funded by a fellowship from 'la Caixa' Foundation (ID 100010434). The fellowship code is LCF/BQ/PR19/11700007. This study has been partially supported by the University of Granada, Plan Propio de Investigación 2016, Excellence actions: Units of Excellence, and Unit of Excellence on Exercise and Health (UCEES), and by the Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades and European Regional Development Fund (ERDF), ref. SOMM17/6107/UGR. The funders had no role in the design of this study, in the collection, analyses or interpretation of the data, in the writing of the manuscript or in the decision to submit the manuscript for publication.
Subjects: Male, Calidad de vida, Physical fitness, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design [Medical Subject Headings], law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Study Protocol, 0302 clinical medicine, Quality of life, Randomized controlled trial, Cancer Survivors, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities::Exercise Therapy::Plyometric Exercise [Medical Subject Headings], law, Bone Density, Huesos, Child, Cancer, Anatomy::Musculoskeletal System::Skeleton::Bone and Bones [Medical Subject Headings], education.field_of_study, lcsh:Public aspects of medicine, Pediatría, Telemedicina, Diseases::Neoplasms [Medical Subject Headings], Neoplasias, Telemedicine, Exercise Therapy, Research Design, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Quality of Life [Medical Subject Headings], Female, Persons::Persons::Patients::Survivors [Medical Subject Headings], Survivor, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities::Exercise Therapy [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Program Evaluation [Medical Subject Headings], Plyometric exercise, medicine.medical_specialty, Adolescent, Population, Check Tags::Male [Medical Subject Headings], 030209 endocrinology & metabolism, Persons::Persons::Age Groups::Adolescent [Medical Subject Headings], Sobrevivientes, Information Science::Information Science::Communications Media::Telecommunications::Telemedicine [Medical Subject Headings], 03 medical and health sciences, Trabecular bone score, medicine, Humans, Persons::Persons::Age Groups::Child [Medical Subject Headings], education, Bone, Ejercicio pliométrico, Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Bone Density [Medical Subject Headings], business.industry, Public health, Public Health, Environmental and Occupational Health, lcsh:RA1-1270, Paediatrics, 030229 sport sciences, Anthropometry, Mental health, Check Tags::Female [Medical Subject Headings], Physical therapy, business, Program Evaluation
Abstract: Background: New approaches on paediatric cancer treatment aim to maintain long-term health. As a result of radiotherapy, chemotherapy or surgery, paediatric cancer survivors tend to suffer from any chronic health condition. Endocrine dysfunction represents one of the most common issues and affects bone health. Exercise is key for bone mass accrual during growth, specifically plyometric jump training. The iBoneFIT study will investigate the effect of a 9-month online exercise programme on bone health in paediatric cancer survivors. This study will also examine the effect of the intervention on body composition, physical fitness, physical activity, calcium intake, vitamin D, blood samples quality of life and mental health. Methods: A minimum of 116 participants aged 6 to 18 years will be randomized into an intervention (n = 58) or control group (n = 58). The intervention group will receive an online exercise programme and diet counselling on calcium and vitamin D. In addition, five behaviour change techniques and a gamification design will be implemented in order to increase the interest of this non-game programme. The control group will only receive diet counselling. Participants will be assessed on 3 occasions: 1) at baseline; 2) after the 9 months of the intervention; 3) 4 months following the intervention. The primary outcome will be determined by dual energy X-ray absorptiometry (DXA) and the hip structural analysis, trabecular bone score and 3D-DXA softwares. Secondary outcomes will include anthropometry, body composition, physical fitness, physical activity, calcium and vitamin D intake, blood samples, quality of life and mental health., La Caixa Foundation 100010434 LCF/BQ/PR19/11700007, University of Granada, Plan Propio de Investigacion 2016, Excellence actions: Units of Excellence; Unit of Excellence on Exercise and Health (UCEES), Junta de Andalucía SOMM17/6107/UGR, European Union (EU) SOMM17/6107/UGR
Published: 2020

16. Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study)

Author: Carlos Suso-Ribera, Francesco D'Amico, Antonio Cuesta-Vargas, Juan P. Sanabria-Mazo, Antoni Sanz, Juan R. Castaño-Asins, Pere Estivill-Rodríguez, Paula Cristóbal-Narváez, Albert Feliu-Soler, Adrián Pérez-Aranda, Grasa Mm, Antonio Montes-Pérez, Azucena García-Palacios, Lance M. McCracken, Carlos G. Forero, Michael Maes, Araceli Rosa, Xavier Borrás, Juan V. Luciano, Ariadna Colomer-Carbonell, Bernat Carreras-Marcos, Laura Andrés-Rodríguez, Silvia Edo, Olga Comps-Vicente, Montserrat Esteve, This study has been funded by the Institute of Health Carlos III (ISCIII, and PI19/00112 & PI16/00165 have been cofinanced with European Union ERDF funds). JVL has a 'Miguel Servet Type II' contract from the ISCIII (CPII19/00003). ISCIII did not have any role in the analysis and interpretation of data, in the writing of the manuscript and in the decision to submit the paper for publication.
Subjects: Technology, General Practice, lcsh:Medicine, Impact study, Chronic pain, R Medicine (General), Acceptance and commitment therapy, law.invention, Clinical trials, Randomized controlled trial, Terapia de aceptación y compromiso, law, Depresión, Tratamiento breve de activación conductual para la depresión, Dolor persistente, Persistent pain, Medicine, Multicenter Studies as Topic, Depressió psíquica, Depression (differential diagnoses), Applied Psychology, Randomized Controlled Trials as Topic, Ecology, Depression, Teràpia racional emotiva conductual, General Medicine, Dolor crònic, Chronic low back pain, Mental depression, Rational emotive behavior therapy, BF Psychology, Ecological Momentary Assessment, Clinical trials, Depression & mood disorders, pain management, Brief behavioral activation treatment for depression, 159.9, Health Economics, Dolor lumbar crónico, Humans, Tractament breu d’activació conductual per a la depressió, Acceptance and Commitment Therapy, Protocol (science), Dolor lumbar crònic, business.industry, lcsh:R, Teràpia d’acceptació i compromís, Dolor persistent, Tillämpad psykologi, Pain management, Clinical trial, Allmänmedicin, pain management, Spain, Depression & mood disorders, Economic evaluation, Depressió, business, Low Back Pain
Abstract: IntroductionThe IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre–post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes.Methods and analysisParticipants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed.Ethics and disseminationThis study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities.Trial registration numberNCT04140838
Published: 2020

17. Low serum DHEA-S is associated with impaired lung function in women

Author: Thorarinn Gislason, Isabelle Pin, Nicole Probst-Hensch, Jesús Martínez-Moratalla, Bénédicte Leynaert, Alessandro Marcon, Judith Garcia-Aymerich, Sandra Dorado-Arenas, Pascal Demoly, Rain Jõgi, Deborah Jarvis, Joachim Heinrich, Torben Sigsgaard, Josep M. Antó, Eva Lindberg, Jose Antonio Gullón-Blanco, Elisabeth Zemp, Dennis Nowak, Chantal Raherison, Kai Triebner, Shyamali C. Dharmage, Diana A van der Plaat, José Luis Sánchez-Ramos, Kjell Torén, Bertil Forsberg, Giancarlo Pesce, Steinar Hustad, Francisco Gómez-Real, Dominique Courbon, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Bergen (UiB), National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Aarhus University Hospital, Institute of Epidemiology [Neuherberg] (EPI), German Research Center for Environmental Health - Helmholtz Center München (GmbH), IMIM-Hospital del Mar, Generalitat de Catalunya, Laboratoire de Biotechnologie et Microbiologie Appliquée (LBMA), Université Bordeaux Segalen - Bordeaux 2-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] (Brain Tech Lab ), CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Sahlgrenska Academy at University of Gothenburg [Göteborg], Umeå University, Uppsala University Hospital, University of Basel (Unibas), Imperial College London, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Agence Nationale de la Recherche, ANR 633212 ComitÃ© des Maladies Respiratoires de l'IsÃ¨re European Commission, EC: QLK4-CT-1999–01237 Norges ForskningsrÃ¥d: 228174 Institut National de la SantÃ© et de la Recherche MÃ©dicale, Inserm: U700 Agence Nationale de la Recherche, ANR Medical Research Council, MRC: 92091 Composites Innovation Centre, CIC Eesti Teadusagentuur: 562, The current study is part of the Ageing for Lungs in European Cohorts (ALEC) study ( www.alecstudy.org ), ALEC has received funding from the European Union's Horizon 2020 research and innovation program [grant agreement No. 633212]. The coordination of the ECRHS was supported by the European Commission [grant agreement no. QLK4-CT-1999–01237] and the Medical Research Council [grant agreement no. 92091]. The hormones measures at ECRHS III were funded by the Norwegian Research Council [grant agreement no. 228174]. Hormones measures at ECRHS II were funded by the local budget of the ECRHS Paris team, INSERM U700, Epidemiology, with further support from the Comité National contre les Maladies Respiratoires (CNMR), the centre d'Investigation Clinique (CIC), Bichat Hospital, and the French Agence Nationale de la Recherche (ANR). Bodies funding the local studies are listed in the Online Supplement. The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication., Dr Demoly reports presentation honoraria from Stallergène Greer, ALK, Mylan, Astra Zeneca, Bausch&Lomb and personal fees as board advisor from Chiesi, Sanofi, Thermo Fisher Scientific, outside the submitted work. Dr Jogi reports personal grants from the Estonian Research Council [personal research grant no.562], and reports travel grants and presentation honoraria from GSK, Novartis, Boehringer, outside the submitted work. Dr Pin reports travel grants and presentation honoraria from GSK, Novartis, Astra Zeneca, Zambon Pharma, outside the submitted work. All the authors declare no competing interests., European Project: 633212,H2020,H2020-PHC-2014-two-stage,ALEC(2015), Læknadeild (HÍ), Faculty of Medicine (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, University of Iceland, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
Subjects: Research paper, Respiratory Medicine and Allergy, [SDV]Life Sciences [q-bio], Population, Physiology, Dehydroepiandrosterone, Endocrinology and Diabetes, 01 natural sciences, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Dehydroepiandrosterone sulfate, Karlhormónar, Medicine, Airflow obstruction, Sex hormones, 030212 general & internal medicine, 0101 mathematics, education, Kynhormónar, Testosterone, Lungmedicin och allergi, 2. Zero hunger, lcsh:R5-920, education.field_of_study, business.industry, Incidence (epidemiology), Öndunarfæri, 010102 general mathematics, EPICENE, Public Health, Global Health, Social Medicine and Epidemiology, General Medicine, 3. Good health, Airflow Obstruction, Androgens, Cohort Studies, Sex Hormones, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, chemistry, Endokrinologi och diabetes, Cohort studies, lcsh:Medicine (General), business, Body mass index, hormones, hormone substitutes, and hormone antagonists, Cohort study, Hormone
Abstract: Publisher's version (útgefin grein), Background: Emerging evidence suggests that androgens and estrogens have a role in respiratory health, but it is largely unknown whether levels of these hormones can affect lung function in adults from the general population. This study investigated whether serum dehydroepiandrosterone sulfate (DHEA-S), a key precursor of both androgens and estrogens in peripheral tissues, was related to lung function in adult women participating in the European Community Respiratory Health Survey (ECRHS). Methods: Lung function and serum DHEA-S concentrations were measured in n = 2,045 and n = 1,725 women in 1999–2002 and in 2010–2013, respectively. Cross-sectional associations of DHEA-S levels (expressed as age-adjusted z-score) with spirometric outcomes were investigated, adjusting for smoking habits, body mass index, menopausal status, and use of corticosteroids. Longitudinal associations of DHEA-S levels in 1999–2002 with incidence of restrictive pattern and airflow limitation in 2010–2013 were also assessed. Findings: Women with low DHEA-S (z-score, The current study is part of the Ageing for Lungs in European Cohorts (ALEC) study ( www.alecstudy.org ), ALEC has received funding from the European Union's Horizon 2020 research and innovation program [grant agreement No. 633212]. The coordination of the ECRHS was supported by the European Commission [grant agreement no. QLK4-CT-1999–01237] and the Medical Research Council [grant agreement no. 92091]. The hormones measures at ECRHS III were funded by the Norwegian Research Council [grant agreement no. 228174]. Hormones measures at ECRHS II were funded by the local budget of the ECRHS Paris team, INSERM U700, Epidemiology, with further support from the Comité National contre les Maladies Respiratoires (CNMR), the centre d'Investigation Clinique (CIC), Bichat Hospital, and the French Agence Nationale de la Recherche (ANR). Bodies funding the local studies are listed in the Online Supplement. The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Published: 2020
Full Text: View/download PDF

18. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)

Author: Barré, Tangui, Nishimwe, Marie Libérée, Protopopescu, Camelia, Marcellin, Fabienne, Carrat, Fabrice, Dorival, Céline, Delarocque-Astagneau, Elisabeth, Larrey, Dominique G., Bourlière, Marc, Petrov-Sanchez, Ventzislava, Simony, Mélanie, Pol, Stanislas, Fontaine, Hélène, Carrieri, Patrizia Maria, Pageaux, Georges Philippe, HAL UVSQ, Équipe, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Biostatistique, Biomathématique, Pharmacoépidémiologie et Maladies Infectieuses (B2PHI), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Merck Sharp and Dohme, MSD Agence Nationale de la Recherche, ANR AbbVie Bristol-Myers Squibb, BMS AbbVie Association Française pour l'Etude du Foie, AFEF Roche Gilead Sciences Shionogi Cilag MSD France, FC reports grants from INSERM-ANRS, during the conduct of the study, and personal fees from Imaxio, outside the submitted work. MB reports grants and personal fees from AbbVie and Gilead, outside the submitted work, and personal fees from MSD, Janssen, Boehringher Ingelheim, Intercept, and Bristol-Myers Squibb, outside the submitted work. SP has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, Roche, MSD, MYR-Pharma, Shionogi, Biotest and Abbvie, as well as grants from Bristol-Myers Squibb, Gilead, Roche and MSD. HF reports personal fees and invitations for medical meetings from Gilead, AbbVie, Bristol-Myers Squibb, MSD, and Janssen, outside the submitted work. Other authors declare no financial support. The cohort received financial support from the INSERM-ANRS (France Recherche Nord & Sud Sida-HIV H?patites), the French ANR (Agence Nationale de la Recherche), the French DGS (Direction Générale de la Santé), Merck Sharp and Dohme, Janssen-Cilag, Gilead, Abbvie, Bristol-Myers Squibb, and Roche. Those funding sources had no role in the writing of the manuscript or the decision to submit it for publication. We thank the study participants and the participating clinicians at each site. We also thank the INSERM-ANRS for sponsoring, funding and conducting the ANRS CO22 Hepather cohort in collaboration with the French Association for the Study of the Liver (Association Fran?aise pour l'Etude du Foie: AFEF). Finally, our thanks to Jude Sweeney for the English revision and editing of our manuscript., On behalf of the ANRS/AFEF Hepather study group : Delphine Bonnet, Virginie Sicart (CHU Purpan, Toulouse, France), François Bailly, Marjolaine Beaudoin, Dominique Giboz, Kerstin Hartig‐Lavie, Marianne Maynard (Hospices Civils de Lyon, Lyon, France), Morane Cavellec, Marjorie Cheraud‐Carpentier, François Raffi, Florian Vivrel (Hôpital Hôtel‐Dieu, Nantes, France), Jaouad Benhida, Jérôme Boursier, Paul Calès, Françoise Lunel, Frédéric Oberti (CHU Angers, Angers, France), Nathalie Boyer, Audrey Gilibert, Nathalie Giuily (Hôpital Beaujon, Clichy, France), Giovanna Scoazec (Hôpital Beaujon, Clichy, France and Hôpital Henri Mondor, Créteil, France), Sandrine Fernandes, Sylvie Keser, Philippe Sultanik, Anaïs Vallet‐Pichard (Hôpital Cochin, Paris, France), Juliette Foucher, Jean‐Baptiste Hiriart, Aurore Mathias, Julien Vergniol (Hôpital Haut‐Lévêque, Pessac, Bordeaux, France), Chrystelle Ansaldi, Laëtitia Chouquet, Emilie De Luca, Valérie Oules (Hôpital Saint Joseph, Marseille, France), Rodolphe Anty, Eve Gelsi, Régine Truchi (CHU de Nice, Nice, France), Elena Luckina, Nadia Messaoudi, Joseph Moussali, (Groupe Hospitalier Pitié‐Salpétrière, Paris, France), Barbara De Dieuleveult, Damien Labarriere, Pascal Poter, Si Nafa Si Ahmed (CHR La Source, Orléans, France), Nathalie Ganne‐Carrié, Véronique Grando‐Lemaire, Pierre Nahon, Alan Peltier, Judith Ung (Hôpital Jean Verdier, Bondy, France), Mariette Gougeon, Anne Guillygomarch, Caroline Jezequel (CHU Rennes, Rennes, France), Romain Moirand, Thomas F. Baumert, Michel Dofföel, Catherine Mutter, Pauline Simo‐Noumbissie (Hôpitaux Universitaires de Strasbourg, Strasbourg, France), Hélène Barraud, Mouni Bensenane, Abdelbasset Nani, Sarah Hassani‐Nani (CHU de Nancy, Vandoeuvre‐lès‐Nancy, France), Marie‐Albertine Bernard (CHU de Nancy, Vandoeuvre‐lès‐Nancy, France and Centre Hospitalier Régional, Metz, France), Michael Bismuth, Ludovic Caillo, Stéphanie Faure, Georges‐Philippe Pageaux, Marie Pierre Ripault (Hôpital Saint Eloi, Montpellier, France), Karl Barange, Christophe Bureau, Jean Marie Peron, Marie Angèle Robic, Léa Tarallo (CHU Purpan, Toulouse, France), Marine Faure, Bruno Froissart, Marie‐Noelle Hilleret, Vincent Leroy (CHU de Grenoble, Grenoble, France), Odile Goria, Victorien Grard, Hélène Montialoux (CHU Charles Nicolle, Rouen, France), Muriel François, Christian Ouedraogo, Christelle Pauleau, Anne Varault (Hôpital Henri Mondor, Créteil, France), Tony Andreani, Bénédicte Angoulevant, Azeline Chevance, Lawrence Serfaty (Hôpital Saint‐Antoine, Paris, France), Teresa Antonini, Audrey Coilly, Jean‐Charles Duclos Vallée, Mariagrazia Tateo (Hôpital Paul Brousse, Villejuif, France), Armand Abergel, Corinne Bonny, Chanteranne Brigitte, Géraldine Lamblin, Léon Muti (Hôpital Estaing, Clermont‐Ferrand, France), Abdenour Babouri, Virginie Filipe (Centre Hospitalier Régional, Metz, France), Camille Barrault, Laurent Costes, Hervé Hagège, Soraya Merbah (Centre Hospitalier Intercommunal, Créteil, France), Paul Carrier, Maryline Debette‐Gratien, Jérémie Jacques (CHU Limoges, Limoges, France), Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet (CHRU Claude Huriez, Lille, France), Marc Bardou, Donya Da Costa Souhiel, Patrick Hillon, Marianne Latournerie (Dijon University Hospital, Dijon, France), Yannick Bacq, Didier Barbereau, Charlotte Nicolas (CHU Trousseau, 37044 Tours, France), Nisserine Ben Amara, Danièle Botta‐Fridlund, Isabelle Portal (CHU Timone, Marseille, France), Moana Gelu‐Simeon, Marie‐Josée Lafrance (CHU de Pointe‐à‐Pitre, Pointe‐à‐Pitre, Guadeloupe)., Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Liver Cirrhosis, cannabis, medicine.medical_specialty, Population, HIV Infections, 030209 endocrinology & metabolism, marijuana smoking, Lower risk, 03 medical and health sciences, 0302 clinical medicine, Insulin resistance, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Diabetes mellitus, Internal medicine, medicine, Humans, Risk factor, education, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, education.field_of_study, Hepatology, biology, business.industry, 1. No poverty, Hepatitis C, Hepatitis C, Chronic, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, biology.organism_classification, 3. Good health, chronic, Cross-Sectional Studies, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Cohort, diabetes mellitus, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030211 gastroenterology & hepatology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cannabis, France, business
Abstract: International audience; Chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, and HCV-infected patients are at a high risk of developing diabetes. In the general population, research has shown the potential benefit of cannabis use for the prevention of diabetes and related metabolic disorders. We aimed to test whether cannabis use is associated with a lower risk of diabetes in chronic HCV-infected patients. Chronic HCV-infected patients (n = 10 445) were selected from the French national, multicenter, observational ANRS CO22 Hepather cohort. Cross-sectional data collected at cohort enrollment were used to assess the association between patients’ clinical and behavioural characteristics and the risk of diabetes. Logistic regression model was performed with cannabis use as the main independent variable and a significance level set at 5%. A similar model stratified by the presence of advanced liver fibrosis (FIB-4 > 3.25) was also run. After multivariable adjustment, current (AOR [95%CI]: 0.49 [0.38-0.63]) and former (0.81 [0.67-0.98], P
Published: 2020
Full Text: View/download PDF

19. High Prevalence of Leptospira spp. in Rodents in an Urban Setting in Madagascar

Author: Minoarisoa Rajerison, Benoit Garin, Soanandrasana Rahelinirina, Fehivola Andriamiaramanana, Pascale Bourhy, Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP), Biologie des Spirochètes / Biology of Spirochetes, Institut Pasteur [Paris], CHU Pointe-à-Pitre/Abymes [Guadeloupe], We would like to thank the staff of the Plague Unit, Institut Pasteur Madagascar for field and technical assistance, and the team of the Centre National de Référence de la Leptospirose, Institut Pasteur, Paris for technical assistance genotyping isolates. We thank D. Wagner for improving the English writing in the manuscript., and Institut Pasteur [Paris] (IP)
Subjects: MESH: Leptospira interrogans, Veterinary medicine, [SDV]Life Sciences [q-bio], animal diseases, 030231 tropical medicine, MESH: Rodentia, MESH: Leptospira, law.invention, MESH: Madagascar, 03 medical and health sciences, 0302 clinical medicine, law, Leptospira, Virology, MESH: Cities, medicine, MESH: Animals, 030212 general & internal medicine, MESH: Prevalence, Polymerase chain reaction, High prevalence, Bacterial disease, biology, MESH: Kidney, MESH: Leptospirosis, bacterial infections and mycoses, biology.organism_classification, medicine.disease, MESH: DNA, Bacterial, Leptospirosis, 3. Good health, Leptospira borgpetersenii, Infectious Diseases, Capital city, bacteria, Parasitology, MESH: Rodent Diseases, Leptospira interrogans
Abstract: International audience; Leptospirosis is a neglected zoonotic bacterial disease caused by pathogenic Leptospira spp. Only limited studies have been conducted on the presence of Leptospira spp. in rats in Antananarivo, the capital city of Madagascar. We assessed Leptospira prevalence in small mammals in urban areas of Antananarivo where sanitation is inadequate and there is risk of flooding during the rainy season. We captured rodents and shrews at two sites and examined kidney samples from 114 animals using culture and a real-time polymerase chain reaction (PCR) assay specific to pathogenic Leptospira spp. We identified 23 positive samples containing Leptospira interrogans and Leptospira borgpetersenii, with a high prevalence in Rattus norvegicus (44.9%). Our results indicate that small mammals, in particular R. norvegicus, present a major public health risk for acquiring leptospirosis in Antananarivo.
Published: 2019
Full Text: View/download PDF

20. Effectiveness of a Mindfulness and Self-Compassion Standard Training Program versus an Abbreviated Training Program on Stress in Tutors and Resident Intern Specialists of Family and Community Medicine and Nursing in Spain

Author: Juan Carlos, Verdes-Montenegro-Atalaya, Luis Ángel, Pérula-de Torres, Norberto, Lietor-Villajos, Cruz, Bartolomé-Moreno, Herminia, Moreno-Martos, Luis Alberto, Rodríguez, Teresa, Grande-Grande, Rocío, Pardo-Hernández, Benito, León-Del-Barco, Mirian, Santamaría-Peláez, Luis A, Mínguez, Josefa, González-Santos, Raúl, Soto-Cámara, Jerónimo J, González-Bernal, On Behalf Of The Minduudd Collaborative Study Group, On Behalf Of The Minduudd Collaborative Study Group, [Verdes-Montenegro-Atalaya,JC, Grande-Grande,T] Family and Community Medicine Teaching Department of Burgos, Burgos, Spain. [Pérula-de Torres,LÁ] Multi-Professional Teaching Unit for Family and Community Care of Cordoba, Healthcare District of Cordoba and Guadalquivir, Institute Maimonides Research Institute Cordoba (IMIBIC), Reina Sofía University Hospital, University of Cordoba, Cordoba, Spain. [Lietor-Villajos,N] Family and Community Medicine Teaching Department of Jaen, Jaen, Spain. [Bartolomé-Moreno,C] Family and Community Medicine Teaching Department of Zaragoza Sector 1, Zaragoza, Spain. [Moreno-Martos,H] Multi-Professional Teaching Unit for Family and Community Care of Almería, Almería, Spain. [Rodríguez,LA] Family and Community Medicine Teaching Department of Ponferrada, León, Spain. [Pardo-Hernández,R, Santamaría-Peláez,M, González-Santos,J, Soto-Cámara,R, González-Bernal,JJ] Department of Health Sciences, University of Burgos, Burgos, Spain. [León-Del-Barco,B] Department of Psychology, Faculty of Teacher Training College, University of Extremadura, Caceres, Spain. [Mínguez,LA] Department of Educational Sciences, University of Burgos, Burgos, Spain., and This project has received an 'Isabel Fernández, 2017' scholarship from the Andalusian Society of Family and Community Medicine (SAMFyC, Ref. 153/17). On the other hand, it has received funding in the call for research and innovation projects in the field of Primary Care of the Andalusian Health Service (Ref. AP-0155-2018). The funding source had no influence on the design of the study, data collection and analysis, or the writing of the manuscript.
Subjects: mindfulness, Mindfulness, Health, Toxicology and Mutagenesis, España, MBSR, Stress level, law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], stress, Randomized controlled trial, law, Surveys and Questionnaires, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Stress, Psychological [Medical Subject Headings], Stress (linguistics), media_common, Estudiantes del area de la salud, PSQ, Primary care, Resident intern specialists, Encuestas y Cuestionarios, Tutors, Estrés fisiológico, Community Medicine, Atención plena, tutors, Medicine, Training program, Psychology, Self-compassion, Atención primaria de la salud, media_common.quotation_subject, education, Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychotherapy::Behavior Therapy::Cognitive Therapy::Mindfulness [Medical Subject Headings], Empathy, Stress, Article, Information Science::Information Science::Data Collection::Questionnaires [Medical Subject Headings], primary care, Nursing, Intervention (counseling), Humans, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Disciplines and Occupations::Health Occupations::Medicine::Community Medicine [Medical Subject Headings], Public Health, Environmental and Occupational Health, resident intern specialists, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Personality::Empathy [Medical Subject Headings], Spain, Stress, Psychological
Abstract: Stress is one of the most common problems among healthcare professionals, as they are exposed to potentially stressful and emotionally challenging situations in the workplace. Mindfulness-based stress reduction (MBSR) training programs have been shown to decrease stress. The objective of this study was to compare the effectiveness of an abbreviated 4-weeks MBSR training program in relation to a standard 8-weeks one on the stress levels. A controlled and randomized clinical trial was designed, in which 112 tutors and resident intern specialists in Family and Community Medicine and Nursing of six Spanish National Health System teaching units (TUs) participated. Participants included in the experimental groups (EGs) received a MBRS training program (standard or abbreviated), while control group (CG) participants did not receive any intervention. The stress levels were assessed by the Perceived Stress Questionnaire (PSQ) in three different moments during the study: before, immediately after, and 3 months after the intervention. Adjusted covariance analysis (ANCOVA), using pretest scores as the covariate, showed a significant reduction in stress (F(2,91) = 5.165, p = 0.008, η2 = 0.102) in the post-test visit, attributable to the implementation of the standard training program, but without the maintenance of its effects over time. No significant impact of the abbreviated training program on stress levels was observed in the intergroup comparison. A standard 8-weeks MBSR training program aimed at tutors and resident intern specialists in Family and Community Medicine and Nursing produces significant improvements in stress levels compared with the abbreviated intervention and no intervention. New studies about abbreviated training programs are needed to provide effective treatments which improve well-being of these professionals.
Published: 2021
Full Text: View/download PDF

21. Efficacy of the In2Care® auto-dissemination device for reducing dengue transmission: study protocol for a parallel, two-armed cluster randomised trial in the Philippines

Author: Ariza Aguila, Marianette T. Inobaya, Ava Kristy Sy, Edward K. Thomsen, Jason R. Angeles, Michael J. Bangs, Ferdinand V. Salazar, Richard Paul, Tom Toner, Research Institute for Tropical Medicine [Muntinlupa City, Philippines], Liverpool School of Tropical Medicine (LSTM), Kasetsart University - KU (THAILAND), Kasetsart University (KU), PT Freeport Indonesia/International SOS, Génétique fonctionnelle des maladies infectieuses - Functional Genetics of Infectious Diseases, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Génomique évolutive, modélisation et santé (CNRS-UMR2000), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), This study was funded by the Agence Française de Développement in the context of the Ecomore 2 programme ( www.ecomore.org/ ). The funding body did not have any role in project design or in the writing of this manuscript. The trial sponsor is Institut Pasteur, Paris, France., Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Génomique évolutive, modélisation et santé (GEMS)
Subjects: Male, Insecticides, Mosquito Control, Time Factors, MESH: Philippines, Pyridines, Philippines, Medicine (miscellaneous), MESH: Dengue, Dengue virus, medicine.disease_cause, MESH: Dengue Virus, Dengue fever, law.invention, Dengue, Study Protocol, 0302 clinical medicine, Aedes aegypti, law, Aedes, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, Medicine, MESH: Pest Control, Biological, Pharmacology (medical), MESH: Animals, 030212 general & internal medicine, Chikungunya, MESH: Incidence, Child, MESH: Beauveria, Randomized Controlled Trials as Topic, MESH: Mosquito Control, lcsh:R5-920, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, biology, Incidence, MESH: Aedes, 3. Good health, Mosquito control, Transmission (mechanics), Host-Pathogen Interactions, Female, MESH: Mosquito Vectors, lcsh:Medicine (General), Adolescent, Context (language use), Mosquito Vectors, 03 medical and health sciences, Environmental health, Animals, Humans, Beauveria, Pest Control, Biological, MESH: Adolescent, Beauvaria, MESH: Humans, business.industry, MESH: Host-Pathogen Interactions, MESH: Pyridines, MESH: Time Factors, Dengue Virus, medicine.disease, biology.organism_classification, MESH: Male, MESH: Insecticides, MESH: Randomized Controlled Trials as Topic, Pyriproxyfen, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Auto-dissemination, business, MESH: Female, 030217 neurology & neurosurgery
Abstract: Background Mosquito-borne viruses are imposing an ever increasing health burden worldwide. In addition to the recent Zika and chikungunya virus epidemics, dengue viruses have become the fastest growing problem with a 40-fold increase in the number of reported cases over the past five decades. Current mosquito control techniques involving larval source reduction, larviciding, and space spray of adulticides are costly, laborious, and of debatable efficacy. There remains an urgent need for the development of intervention methods that can be reasonably implemented in the context of modern day urbanisation. Auto-dissemination (AD) of insecticide by adult mosquitoes offers a potentially practical and useful tool in an integrated vector control programme. Recently, an immediately employable AD device, the In2Care® mosquito trap, has been commercialised and shows promise as an effective tool. However, there remains a lack of demonstration of epidemiological efficacy. Methods/design This trial aims to assess the extent to which implementation of In2Care® mosquito traps can reduce vector Aedes (Stegomyia) spp. adult mosquito densities and dengue virus transmission as measured by sequential sero-conversion rates in children 6–16 years of age in a dengue endemic location: Lipa City, Philippines. To achieve this, we will carry out a parallel, two-armed cluster randomised trial evaluating AD efficacy for reducing the incidence of dengue over a 2-year period with 4 consecutive months of vector control during peak dengue transmission each year. Discussion For decades, it has been commonly accepted that an integrated approach to mosquito control is required. The World Health Organization (WHO) Global Strategic Framework for Integrated Vector Management recommends a range of interventions, in combination, to increase control impact to reduce transmission. This efficacy trial of the first commercial product using the AD approach will be informative in assessing the general utility of AD in reducing not only adult vector densities but, more importantly, reducing the incidence of dengue. The AD technique may complement source reduction and larviciding campaigns by more efficiently targeting the most productive containers and those beyond human reach. If successful, this mosquito control strategy could prove an invaluable tool in the fight against urban mosquito vectors and a reduction in the burden of associated disease. Trial registration ISRCTN44272773. Registered on 31 January 2019. Electronic supplementary material The online version of this article (10.1186/s13063-019-3376-6) contains supplementary material, which is available to authorized users.
Published: 2019
Full Text: View/download PDF

22. Blood lead level in infants and subsequent risk of malaria : a prospective cohort study in Benin, Sub-Saharan Africa

Author: Jacqueline Milet, Michel Cot, André Garcia, Florence Bodeau-Livinec, Amanda Garrison, David Courtin, Pierre Ayotte, Achille Massougbodji, Babak Khoshnood, Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), Université Paris Descartes - Paris 5 (UPD5)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Institut de Recherche Clinique du Bénin [Abomey-Calavi, Bénin] (IRCB), Institut National de Santé Publique du Québec [Canada] (INSPQ), École des Hautes Études en Santé Publique [EHESP] (EHESP), The Eunice Kennedy Shriver National Institute of Child Health & Human Development (NIH/NICHD) funded the TOVI study, grant R21-HD060524. The MiPPAD trial (NCT00811421) was co-funded by the European and Developing Countries Clinical Trials Partnership (EDCTP-IP.07.31080.002). The 'Anaemia in Pregnancy: Etiologies and Consequences' (APEC) study received funding from a grant from the Bill and Melinda Gates Foundation. The TOLIMMUNPAL project was funded by the French ANR (Agence Nationale de la Recherche) and coordinated by Dr André Garcia (IRD, UMR 216). Amanda Garrison received funding from PRINCEPS (Université Sorbonne Paris Cité) during the writing of this manuscript., ANR-10-PRSP-0012,TOLIMMUNPAL(2010), Bodescot, Myriam, PROGRAMME DE RECHERCHE EN SANTE PUBLIQUE - - TOLIMMUNPAL2010 - ANR-10-PRSP-0012 - PRSP - VALID, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), and Mère et enfant face aux infections tropicales (MERIT - UMR_D 216)
Subjects: Male, Multivariate statistics, Pediatrics, Epidemiology, Health, Toxicology and Mutagenesis, 010501 environmental sciences, Biochemistry, 01 natural sciences, Geographical Locations, Families, Mathematical and Statistical Techniques, 0302 clinical medicine, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Benin, 030212 general & internal medicine, Prospective cohort study, Children, Protozoans, Global and Planetary Change, Multidisciplinary, medicine.diagnostic_test, Incidence, Nutritional Deficiencies, Statistics, Eukaryota, Pollution, 3. Good health, [SDV.TOX] Life Sciences [q-bio]/Toxicology, Chemistry, Quartile, [SDV.TOX]Life Sciences [q-bio]/Toxicology, Physical Sciences, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Regression Analysis, Medicine, Female, medicine.symptom, Research Article, Chemical Elements, medicine.medical_specialty, Blood chemistry, Science, Protective factor, Research and Analysis Methods, Risk Assessment, Asymptomatic, 03 medical and health sciences, Malarial parasites, parasitic diseases, Parasitic Diseases, medicine, Metallic lead, Humans, Statistical Methods, Africa South of the Sahara, Nutrition, 0105 earth and related environmental sciences, business.industry, Iron deficiency, Organisms, Public Health, Environmental and Occupational Health, Univariate, Infant, Biology and Life Sciences, Tropical Diseases, medicine.disease, Parasitic Protozoans, Malaria, Lead, Age Groups, People and Places, Africa, Population Groupings, Blood lead level, business, Linear regression analysis, Mathematics, Follow-Up Studies
Abstract: International audience; Lead and malaria both present significant health risks to children in Sub-Saharan Africa. Previous studies have shown that high blood lead levels in children act as a protective factor against subsequent malaria incidence. The main objective of this study was to investigate associations between blood lead level and malaria outcomes prospectively in Beninese children from 12 to 24 months of age. Two-hundred and four children were assessed for lead at 12 months and closely followed until 24 months for malaria; when symptoms and parasite density were also recorded. Univariate and multivariate negative binomial and linear regression models tested associations between blood lead level quartile and total episodes of malaria (total symptomatic and asymptomatic episodes) and parasite density, respectively. Median blood lead level among children measured at 12 months was 56.50 (4.81-578) μg/L. During the 12-month follow-up, 172 (84.31%) children had at least one malaria episode. Univariate and multivariate negative binomial and linear regressions did not reveal significant associations between blood lead level quartile and malaria outcomes. Iron deficiency was not found to be an effect modifier. Results from this prospective child-cohort study investigating associations between blood lead level and malaria did not confirm results from previous cross-sectional studies. Further research is needed to further explore this relationship and other co-morbidities due to malaria and lead.
Published: 2019
Full Text: View/download PDF

23. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs

Author: Marion Richard, Didier Hocquet, Didier Mazel, Christine Fagnoni-Legat, Virginie Nerich, Alexandre Meunier, Xavier Bertrand, Olivier Adotevi, Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de pharmacologie, Plasticité du Génome Bactérien - Bacterial Genome Plasticity (PGB), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), This work was supported by the University Hospital of Besançon, France (Grant RAPACE - APICHU 2016). The study sponsor had no role in the design of the study, the collection, analysis and interpretation of the data, the writing of the manuscript or the decision to submit the manuscript for publication, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Service de pharmacie, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), and Plasticité du Génome Bactérien
Subjects: 0301 basic medicine, Microbiology (medical), Staphylococcus aureus, medicine.drug_class, 030106 microbiology, Antibiotics, Antineoplastic Agents, Drug resistance, Microbial Sensitivity Tests, Biology, medicine.disease_cause, Microbiology, 03 medical and health sciences, SOS Response (Genetics), 0302 clinical medicine, Antibiotic resistance, Drug Resistance, Bacterial, Enterobacter cloacae, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Mutation frequency, SOS response, SOS Response, Genetics, Pharmacology, Pathogenic bacteria, Chemotherapy regimen, 3. Good health, Anti-Bacterial Agents, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infectious Diseases, Pseudomonas aeruginosa
Abstract: International audience; BACKGROUND:Infections with antibiotic-resistant pathogens in cancer patients are a leading cause of mortality. Cancer patients are treated with compounds that can damage bacterial DNA, potentially triggering the SOS response, which in turn enhances the bacterial mutation rate. Antibiotic resistance readily occurs after mutation of bacterial core genes. Thus, we tested whether cancer chemotherapy drugs enhance the emergence of resistant mutants in commensal bacteria.METHODS:Induction of the SOS response was tested after the incubation of Escherichia coli biosensors with 39 chemotherapeutic drugs at therapeutic concentrations. The mutation frequency was assessed after induction with the SOS-inducing chemotherapeutic drugs. We then tested the ability of the three most highly inducing drugs to drive the emergence of resistant mutants of major bacterial pathogens to first-line antibiotics.RESULTS:Ten chemotherapeutic drugs activated the SOS response. Among them, eight accelerated the evolution of the major commensal E. coli, mostly through activation of the SOS response, with dacarbazine, azacitidine and streptozotocin enhancing the mutation rate 21.3-fold (P
Published: 2018
Full Text: View/download PDF

24. The 17β-Estradiol induced upregulation of the Adhesion G-protein coupled receptor (ADGRG7) is modulated by ESRα and SP1 complex

Author: Samira Benhadjeba, André Tremblay, Mathieu Lévesque, Shunmoogum A. Patten, Florina Moldovan, Edward T. Bagu, Isabelle Villemure, Amani Hassan, Lydia Edjekouane, CHU Sainte Justine [Montréal], University of South Dakota [Vermillion] (USD), Institut Armand Frappier (INRS-IAF), Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), École Polytechnique de Montréal (EPM), Université de Montréal (UdeM), This work was supported by the Fondation Yves Cotrel-Institut de France by grants to F.M., and S.A.P., The Faculty of Dentistry, Université de Montréal, Fonds Ernest- Charron and The Network for Oral and Bone Health Research by grants to F.M., We thank the MEDITIS program for the salary support (A.H.) and FRQS to S.A.P., and The authors would like to thank Heather Yampolsky for help in editing and writing of the manuscript. We would like also to thank Dr Stefan Parent, Madam Soraya Barchi and Mr Francois Cyril for providing osteoblasts that were used in the study. We are also grateful for the lab of Dr Santos for providing Huh-7 cells.
Subjects: 0301 basic medicine, QH301-705.5, medicine.drug_class, [SDV]Life Sciences [q-bio], ADGRG7, Science, Estrogen receptor, Biology, Estradiol (E2), General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Downregulation and upregulation, medicine, GPR128, Biology (General), Binding site, Receptor, Adhesion G-protein coupled receptor, G protein-coupled receptor, Regulation of gene expression, Osteoblasts, AIS, Estrogen, Gene regulation, Cell biology, 030104 developmental biology, General Agricultural and Biological Sciences, Gastrointestinal function, Research Article
Abstract: The physiological role and the regulation of ADGRG7 are not yet elucidated. The functional involvement of this receptor was linked with different physiological process such as reduced body weight, gastrointestinal function and recently, a gene variant in ADGRG7 was observed in patients with adolescent idiopathic scoliosis. Here, we identify the ADGRG7 as an estrogen-responsive gene under the regulation of estrogen receptor ERα in scoliotic osteoblasts and other cells lines. We found that ADGRG7 expression was upregulated in response to estrogen (E2) in adolescent idiopathic scoliosis (AIS) cells. ADGRG7 promoter studies indicate the presence of an ERα response half site in close vicinity of a specificity protein 1 (SP1) binding site. Mutation of the SP1 site completely abrogated the response to E2, indicating its essential requirement. ChIP confirmed the binding of SP1 and ERα to the ADGRG7 promoter. Our results identify the ADGRG7 gene as an estrogen-responsive gene under the control of ERα and SP1 tethered actions, suggesting a possible role of estrogens in the regulation of ADGRG7. This article has an associated First Person interview with the first author of the paper., Summary: Estrogen plays a significant role in AIS and studying the regulation of ADGRG7 by E2 in AIS cells is essential for understanding molecular mechanisms underlying AIS pathogenesis.
Published: 2018
Full Text: View/download PDF

25. The use of FDI criteria in clinical trials on direct dental restorations: A scoping review

Author: Brigitte Grosgogeat, Thomas Marquillier, M Pérard, Florence Chemla, Pierre Millet, Justine Le Clerc, Jean-Christophe Maurin, Sophie Doméjean, Kerstin Gritsch, Elisabeth Dursun, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Recherche en Odontologie Clinique - Clermont Auvergne (CROC), Université Clermont Auvergne (UCA), Université de Rennes 1 - UFR d'Odontologie (UR1 Odontologie), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut des Sciences Chimiques de Rennes (ISCR), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Faculté de Chirurgie Dentaire (UPD5 Odontologie), Université Paris Descartes - Paris 5 (UPD5), Laboratoire des Multimatériaux et Interfaces (LMI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université des Sciences et de la Technologie Houari Boumediene [Alger] (USTHB), Centre Hospitalier Universitaire de Reims (CHU Reims), Unité de Recherche Biomatériaux Innovants et Interfaces (URB2i - EA 4462), Université Paris Descartes - Paris 5 (UPD5)-Université Paris 13 (UP13), To the DECAT collaborative group, especially the team of Pr Gueyffier (coordination) and the Hospices Civils of Lyon (sponsor).This review is in relation with the DECAT study (DEep Caries Treatment). This clinical trial received a PHRC grant (which is a French funding source for hospital clinical trial) from the ministry of health (DGOS). This funding source had neither involvement in the study design, in the analysis, collection and interpretation of data nor in the writing of this manuscript. Tothe corresponding authors of the included studies, whoanswered the questionnaire. To Maxime Faure, who contributed to this publication as part of his end-of-studies thesis in Dental Surgery (University Lyon 1, France). To Misha Dhuper (University of Ottawa), who reviewed the English language in this manuscript.., Centre de Recherche en Odontologie Clinique (CROC), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), UFR d’Odontologie, Université de Lyon, Hospices Civils de Lyon (HCL), Université Paris 13 (UP13)-Université Paris Descartes - Paris 5 (UPD5), Université de Rennes - UFR d'Odontologie (UR Odontologie), Université de Rennes (UR), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université des Sciences et de la Technologie Houari Boumediene = University of Sciences and Technology Houari Boumediene [Alger] (USTHB), Université de Reims Champagne-Ardenne (URCA), and Institut de Thermique, Mécanique, Matériaux (ITheMM)
Subjects: Databases, Factual, Surface Properties, Direct dental restorations, Clinical assessment, MEDLINE, Color, Dentistry, Dental Caries, Composite Resins, 03 medical and health sciences, 0302 clinical medicine, Usphs criteria, Humans, Medicine, Tooth Erosion, Clinical significance, Dental Restoration Failure, 030212 general & internal medicine, Dental Restoration, Permanent, Restorative dentistry, General Dentistry, Clinical Trials as Topic, FDI criteria, business.industry, Retrospective cohort study, 030206 dentistry, Dental Marginal Adaptation, Dentin Sensitivity, Clinical judgment, Clinical trial, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract: OBJECTIVES: A scoping review was conducted to explore the use of FDI criteria 10 years after their introduction. The first aim was to compare the amount of studies using the FDI and/or the modified USPHS criteria. The second aim was to analyse the use of the FDI criteria in clinical trials evaluating direct dental restorations. DATA: Listing of studies using FDI and/or USPHS criteria per year since 2007. Clinical studies related to the assessment of direct restorations using FDI criteria. SOURCE: Two systematic searches - regarding the use of FDI and modified USPHS criteria - were carried out on Medline/Pubmed in order to identify the studies published between 2007 and 2017. Authors of the included articles were contacted to clarify their choice of FDI criteria in their studies. ClinicalTrials.gov database was also queried for the on-going studies that use FDI and modified USPHS criteria. STUDY SELECTION: In the first review, all the clinical trials (randomized/non-randomized, controlled, prospective/retrospective studies) that used FDI criteria to evaluate direct restorations on primary or permanent teeth were included. CONCLUSIONS: 16.3% of the studies used FDI criteria. The percentage of studies using them increased from 4.5% in 2010 to 50.0% in 2016. In average, 8.5 FDI criteria were used. The most employed criteria were: marginal adaptation (96.7%), staining (90.0%), fracture of material and retention (90.0%), recurrence of caries/erosion/abfraction (90.0%), post-operative sensitivity/tooth vitality (86.7%) and surface luster (60.0%). In addition, among the 27 on-going studies from ClinicalTrials.gov database, 51.9% use FDI criteria (including 87.5% with an open recruitment status). CLINICAL SIGNIFICANCE: FDI criteria were reported as practical (various and freely selectable), relevant (sensitive as well as appropriate to current restorative materials and clinical studies design), standardized (making comparisons between investigations easier). Investigators should go on using them for a better standardization of their clinical judgment, allowing comparisons with other studies.
Published: 2018
Full Text: View/download PDF

26. Roussouly's sagittal spino-pelvic morphotypes as determinants of gait in asymptomatic adult subjects

Author: Ziad Bakouny, Abir Massaad, Ismat Ghanem, Wafa Skalli, Gaby Kreichati, Elie Saghbini, Ayman Assi, Virginie Lafage, Université Saint-Joseph de Beyrouth (USJ), Institut de Biomécanique Humaine Georges Charpak (IBHGC), Université Sorbonne Paris Nord-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM), New York University Langone Medical Center (NYU Langone Medical Center), NYU System (NYU), This study was supported by the research council of the University of Saint-Joseph (grant number: FM189). The study sponsors were involved in neither the study design, collection, analysis and interpretation of data nor in the writing of the manuscript, and nor in the decision to submit the manuscript for publication.
Subjects: Pelvic tilt, Adult, Male, Pelvic incidence, Kinematics, Adolescent, Posture, Biophysics, Roussouly classification, Osteoarthritis, Walking, Asymptomatic, Sagittal alignment, Pelvis, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Image Interpretation, Computer-Assisted, medicine, Humans, Orthopedics and Sports Medicine, Lumbar lordosis, Gait, Femoroacetabular impingement, 030222 orthopedics, business.industry, Rehabilitation, [SPI.MECA.BIOM]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Biomechanics [physics.med-ph], Anatomy, medicine.disease, Sagittal plane, Spine, Biomechanical Phenomena, medicine.anatomical_structure, Cross-Sectional Studies, Gait analysis, Sciences du vivant, Female, Ankle, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract: Sagittal alignment is known to greatly vary between asymptomatic adult subjects; however, there are no studies on the possible effect of these differences on gait. The aim of this study is to investigate whether asymptomatic adults with different Roussouly sagittal alignment morphotypes walk differently. Ninety-one asymptomatic young adults (46M & 45W), aged 21.6±2.2years underwent 3D gait analysis and full body biplanar X-rays with three-dimensional (3D) reconstructions of their spines and pelvises and generation of sagittal alignment parameters. Subjects were divided according to Roussouly's sagittal alignment classification. Sagittal alignment and kinematic parameters were compared between Roussouly types. 17 subjects were classified as type 2, 47 as type 3, 26 as type 4 but only 1 as type 1. Type 2 subjects had significantly more mean pelvic retroversion (less mean pelvic tilt) during gait compared to type 3 and 4 subjects (type 2: 8.2°; type 3:11.2°, type 4: 11.3°) and significantly larger ROM pelvic obliquity compared to type 4 subjects (type 2: 11.0°; type 4: 9.1°). Type 2 subjects also had significantly larger maximal hip extension during stance compared to subjects of types 3 and 4 (type 2: -11.9°; type 3: -8.8°; type 4: -7.9°) and a larger ROM of ankle plantar/dorsiflexion compared to type 4 subjects (type 2: 31.1°; type 4: 27.9°). Subjects with type 2 sagittal alignment were shown to have a gait pattern involving both increased hip extension and pelvic retroversion which could predispose to posterior femoroacetabular impingement and consequently osteoarthritis. This study was supported by the research council of the University of Saint-Joseph (grant number: FM189). The study sponsors were involved in neither the study design, collection, analysis and interpretation of data nor in the writing of the manuscript; nor in the decision to submit the manuscript for publication.
Published: 2017
Full Text: View/download PDF

27. Evaluation of the performances of six commercial kits designed for dengue NS1 and anti-dengue IgM, IgG and IgA detection in urine and saliva clinical specimens

Author: Anne-Claire Andries, Anavaj Sakuntabhai, Veasna Duong, Sivuth Ong, Philippe Dussart, Paul F. Horwood, Philippe Buchy, Sopheaktra Ros, Unité de Virologie / Virology Unit [Phnom Penh], Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Génétique fonctionnelle des Maladies infectieuses - Functional Genetics of Infectious Diseases, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), The study was supported by Standard Diagnostics, Inc. The funders had no role in study design, in the collection, analysis and interpretation of data, in writing of the manuscript, or in the decision to submit the article for publication. This research also received funding from the European Union Seventh Framework Programme (FP7/2007/2011) under Grant Agreement n°282 378., European Project: 282378,EC:FP7:HEALTH,FP7-HEALTH-2011-single-stage,DENFREE(2012), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
Subjects: 0301 basic medicine, Immunoglobulin A, Saliva, MESH: Reagent Kits, Diagnostic, NS1, Urine, Rapid diagnostic test, MESH: Dengue, Viral Nonstructural Proteins, Dengue virus, medicine.disease_cause, MESH: Dengue Virus, Immunoglobulin G, Dengue fever, Dengue, 0302 clinical medicine, Medicine, MESH: Immunoglobulin G, biology, MESH: Enzyme-Linked Immunosorbent Assay, MESH: Case-Control Studies, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], MESH: Immunoglobulin M, 3. Good health, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Research Article, 030231 tropical medicine, 030106 microbiology, Enzyme-Linked Immunosorbent Assay, Sensitivity and Specificity, Antibodies, 03 medical and health sciences, parasitic diseases, Humans, MESH: Saliva, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Diagnostic, MESH: Immunoglobulin A, MESH: Humans, [SDV.GEN.GPO]Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE], business.industry, Dengue Virus, medicine.disease, MESH: Sensitivity and Specificity, Immunoglobulin M, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Case-Control Studies, Immunology, biology.protein, MESH: Viral Nonstructural Proteins, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Reagent Kits, Diagnostic, [INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM], business
Abstract: Background Rapid diagnostic tests (RDTs) have been commercialized in order to help physicians in dengue diagnosis. Until recently, only blood samples were used for those tests but it has been shown in several studies that urine and saliva can also be employed for dengue diagnosis. RDTs for the detection of NS1 antigen and anti-dengue IgG, IgM and IgA in urine and saliva specimens have thus been developed by Standard Diagnostics. The aim of this study was to evaluate the performances these new commercial assays. Methods Two panels of clinical specimens were used: one for the evaluation of the NS1-detection devices and the second for the evaluation of the antibody-detection kits. Each panel consisted of urine and saliva specimens collected sequentially from 86 patients with a confirmed dengue infection. A total of 291 saliva and 440 urine samples were included in the NS1-evaluation panel and 530 saliva and 528 urine specimens constituted the antibody-evaluation panel. All samples were tested in parallel by in-house ELISAs and by the commercial RDTs. Results The RDTs demonstrated an overall sensitivity of 15.5 %/27.9 %/10.7 % for NS1/IgG/IgA detection in urine samples and 20.4 %/ 34.8 %/11 %/6.2 % for NS1/IgG/IgM/IgA detection in saliva samples. Compared to the in-house NS1 ELISA, the results obtained with the NS1 RDT demonstrated a good correlation with urine samples (kappa coefficient: 0.88) but not with saliva specimens (kappa coefficient: 0.28). RDTs designed for antibody detection in saliva and urine were extremely specific (100 %), but less sensitive than the in-house ELISAs (i.e., reduction of the overall sensitivity by 12.2 % for the RDT designed for IgG detection in urine and by 23.7 % for the RDT detecting anti-DENV IgM in saliva). IgM were not detected in urine, either by RDT or ELISA. Conclusions Although the RDTs evaluated here offer an apparently attractive approach for dengue diagnosis, this study suggests that these new commercial kits would require further improvement to increase the sensitivity. Electronic supplementary material The online version of this article (doi:10.1186/s12879-016-1551-x) contains supplementary material, which is available to authorized users.
Published: 2016
Full Text: View/download PDF

28. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency

Author: Phum Souy, Narann Tops, Saorin Kim, Khem Kosal, Eva Christophel, Chan Vanna, Sinoun Muth, Khon Sothea, Didier Menard, Pascal Ringwald, Sim Kheng, Chuor Meng Char, Po Ly, Alexandra Kerleguer, Walter R. J. Taylor, Pety Tor, Virak Khieu, John Kevin Baird, Steven Bjorge, National Center for Parasitology, Entomology and Malaria Control [Phnom Penh, Cambodia] (CNM), Service de Médecine Tropicale et Humanitaire [Geneva, Suisse], Hôpitaux Universitaires de Genève (HUG), Mahidol Oxford Tropical Medicine Research Unit, University of Oxford [Oxford]-Mahidol University [Bangkok], World Health Organization [Phnom Penh] (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Pailin Referral Hospital [Pailin, Cambodge], Anlong Veng Referral Hospital [Anlong Venh, Cambodge]., Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Pramoy Health Centre [Cambodia], Eijkman Oxford Clinical Research Unit [Jakarta, Indonesie], Eijkman Institute of Molecular Biology [Jakarta, Indonesie], Centre for Tropical Medicine and Global Health [Oxford, UK], Nuffield Department of Medicine [Oxford, UK] (Big Data Institute), University of Oxford [Oxford]-University of Oxford [Oxford], Regional Office of the Western Pacific (WHO), Funding for this study was obtained by PR of WHO Geneva via a grant from UKAid without which this study would not have taken place. We record our profound gratitude to the taxpayers of the United Kingdom. WRJT was part supported by France Expertise International through the 5 % initiative as a consultant to CNM in operational research and he expresses 'ses remerciements profonds au peuple français.' JKB is supported by Wellcome Trust grant B9RJIXO. DM is supported the French Ministry of Foreign Affairs and SKim was part funded by a grant from the Asia Pacific Malaria Elimination Network. None of the funders had any role in study design, data collection, analysis, and interpretation, or writing of the manuscript or in the decision to submit the manuscript for publication., and We wish to express our sincere and profound thanks to the patients who took part in this study and to the nurses and laboratory staff who contributed to its successful and safe execution. We thank our DSMB who reviewed the G6PDd data in real time and provided very valuable and timely responses and advice: Drs Toby Leslie (Chairperson), Chanthap Lon, Isabella Ribeiro and Professor Lucio Luzzatto.
Subjects: Male, Primaquine, Blood transfusion, medicine.medical_treatment, Plasmodium vivax, MESH: Comorbidity, Comorbidity, Pharmacology, Gastroenterology, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, Outcome Assessment, Health Care, Secondary Prevention, 030212 general & internal medicine, Child, Village Malaria Worker, Medicine(all), MESH: Middle Aged, MESH: Secondary Prevention, biology, General Medicine, MESH: Primaquine, Middle Aged, MESH: Plasmodium vivax, 3. Good health, MESH: Glucosephosphate Dehydrogenase Deficiency, Tolerability, Female, Cambodia, G6PD Activity, medicine.drug, Research Article, Adult, medicine.medical_specialty, Anemia, Hemolytic, Adolescent, Anemia, 030231 tropical medicine, Dihydroartemisinin, MESH: Blood Transfusion, MESH: Drug Administration Schedule, Drug Administration Schedule, 03 medical and health sciences, Antimalarials, Internal medicine, parasitic diseases, medicine, Malaria, Vivax, Humans, Blood Transfusion, MESH: Outcome Assessment, Health Care, MESH: Anemia, Hemolytic, MESH: Adolescent, MESH: Humans, business.industry, MESH: Cambodia, MESH: Malaria, Vivax, MESH: Adult, Thick Blood Film, medicine.disease, biology.organism_classification, MESH: Antimalarials, MESH: Male, Hemizygous Male, Regimen, Glucosephosphate Dehydrogenase Deficiency, business, MESH: Female, Glucose-6-phosphate dehydrogenase deficiency
Abstract: Background Primaquine is used to prevent Plasmodium vivax relapse; however, it is not implemented in many malaria-endemic countries, including Cambodia, for fear of precipitating primaquine-induced acute haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency (G6PDd). Reluctance to use primaquine is reinforced by a lack of quality safety data. This study was conducted to assess the tolerability of a primaquine regimen in Cambodian severely deficient G6PD variants to ascertain whether a weekly primaquine could be given without testing for G6PDd. Methods From January 2013 to January 2014, Cambodians with acute vivax malaria were treated with dihydroartemisinin/piperaquine on days (D) 0, 1 and 2 with weekly doses of primaquine 0.75 mg/kg for 8 weeks (starting on D0, last dose on D49), and followed until D56. Participants’ G6PD status was confirmed by G6PD genotype and measured G6PD activity. The primary outcome was treatment completion without primaquine toxicity defined as any one of: (1) severe anaemia (haemoglobin [Hb] 25 % fractional fall in Hb from D0, (3) the need for a blood transfusion, (4) haemoglobinuria, (5) acute kidney injury (an increase in baseline serum creatinine >50 %) or (6) methaemoglobinaemia >20 %. Results We enrolled 75 patients with a median age of 24 years (range 5–63); 63 patients (84 %) were male. Eighteen patients were G6PDd (17/18 had the Viangchan variant) and had D0 G6PD activity ranging from 0.1 to 1.5 U/g Hb (median 0.85 U/g Hb). In the 57 patients with normal G6PD (G6PDn), D0 G6PD activity ranged from 6.9 to 18.5 U/g Hb (median 12 U/g Hb). Median D0 Hb concentrations were similar (P = 0.46) between G6PDd (13 g/dL, range 9.6–16) and G6PDn (13.5 g/dL, range 9–16.3) and reached a nadir on D2 in both groups: 10.8 g/dL (8.2–15.3) versus 12.4 g/dL (8.8–15.2) (P = 0.006), respectively. By D7, five G6PDd patients (27.7 %) had a >25 % fall in Hb, compared to 0 G6PDn patients (P = 0.00049). One of these G6PDd patients required a blood transfusion (D0–D5 Hb, 10.0–7.2 g/dL). No patients developed severe anaemia, haemoglobinuria, a methaemoglobin concentration >4.9 %, or acute kidney injury. Conclusions Vivax-infected G6PDd Cambodian patients demonstrated significant, mostly transient, falls in Hb and one received a blood transfusion. Weekly primaquine in G6PDd patients mandates medical supervision and pre-treatment screening for G6PD status. The feasibility of implementing a package of G6PDd testing and supervised primaquine should be explored. Trial registration The trial was registered on 3/1/2013 and the registration number is ACTRN12613000003774. Electronic supplementary material The online version of this article (doi:10.1186/s12916-015-0441-1) contains supplementary material, which is available to authorized users.
Published: 2015
Full Text: View/download PDF

29. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Author: C Rodríguez-Martin, Bella Pajares, Manuel Ruiz-Borrego, Ana Lluch, MC Cámara, Miguel Martin, Eva Carrasco, Marina Pollán, Antonio Antón, Manuel Ramos, Miguel Ángel Seguí, John R. Mackey, Tadeusz Pienkowski, Olivier Tredan, Charles L. Vogel, Joaquín Gavilá, Emilio Alba, Lourdes Calvo, Álvaro Rodríguez-Lescure, Grupo Español de Investigación de Cáncer de Mama, Sanofi, Bristol-Myers Squibb, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Spanish Breast Cancer Research Group, GEICAM, [Pajares,B, Alba,E] Medical Oncology Department, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain. [Pollán,M] Epidemiology Nacional Center, Instituto de Salud Carlos III, Madrid, Spain. [Martín,M] Medical Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain. [Mackey,J] Medical Oncology Department, Medical Cross Cancer Institute, Edmonton, AB, Canada. [Lluch,A] Hematology-Oncology Department, Hospital Clínico Universitario de Valencia- INCLIVA Health Research Institute, University of Valencia, Valencia, Spain. [Gavila,J] Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain. [Vogel,Ch] Medical Oncology Department, Sylvester Comprehensive Cancer at Deerfield, Miller School of Medicine, Univ. of Miami- Deerfield Bch, Miami, FL, USA. [Ruiz-Borrego,M] Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain. [Calvo,L] Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [Pienkowski,T] Medical Oncology Department, European Health Center, Otwock, Poland. [Rodríguez-Lescure,A] Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain. [Seguí,MA] Medical Oncology Department, Corporación Sanitaria Parc Taulí, Sabadell, Spain. [Trendan,O] Medical Oncology Department, Centre Léon Bérard, Lyon, France. [Antón,A] Medical Oncology Department, Hospital Miguel Servet, Zaragoza, Spain. [Ramos,M] Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain. [Cámara,MdC, Rodríguez-Martín,C, Carrasco,E] Spanish Breast Cancer Research Group, GEICAM, Madrid, Spain., and This work was supported by the Spanish Breast Cancer Research Group (Grupo Español de Investigación de Cáncer de Mama) (GEICAM). No funding was received for the data analyses or the writing of this manuscript. Clinical trials GEICAM/9805 and BCIRG 001 were funded by Sanofi Aventis. GEICAM/9906 and GEICAM/2003-02 were partially funded by Bristol-Myers Squibb. These funding bodies were not involved in the collection and interpretation of the data or in the decision to publish. EA and MM were also supported by FEDER (RECTICC-RD12/0036/0076)
Subjects: Índice de Masa Corporal, Oncology, Receptor, ErbB-2, medicine.medical_treatment, Obesidad, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings], Supervivencia sin Enfermedad, Body Mass Index, Antineoplastic Combined Chemotherapy Protocols, Medicine, Anthracyclines, Young adult, Medicine(all), Hazard ratio, Neoplasias de la Mama, Pronóstico, Femenino, Middle Aged, Prognosis, Chemotherapy regimen, Treatment Outcome, Female, Taxoids, Mastectomy, Research Article, Adult, medicine.medical_specialty, Análisis de Supervivencia, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], Breast Neoplasms, Disease-Free Survival, Young Adult, Breast cancer, Internal medicine, Adjuvant therapy, Humans, Obesity, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, Gynecology, Dose-Response Relationship, Drug, business.industry, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings], Retrospective cohort study, Antineoplásicos, medicine.disease, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Multivariate Analysis, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Neoplasm Recurrence, Local, business, Body mass index
Abstract: Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of such prognostic effects by subtype. RESULTS: Multivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses to that of patients with a BMI < 25 (reference group) in terms of recurrence (Hazard Ratio [HR] = 1.08, 95% Confidence Interval [CI] = 0.90 to 1.30), BCM (HR = 1.02, 0.81 to 1.29), and OM (HR = 0.97, 0.78 to 1.19). Patients with severe obesity (BMI ≥ 35) had a significantly increased risk of recurrence (HR = 1.26, 1.00 to 1.59, P = 0.048), BCM (HR = 1.32, 1.00 to 1.74, P = 0.050), and OM (HR = 1.35, 1.06 to 1.71, P = 0.016) compared to our reference group. The prognostic effect of severe obesity did not vary by subtype. CONCLUSIONS: Severely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes. This work was supported by the Spanish Breast Cancer Research Group (Grupo Español de Investigación de Cáncer de Mama) (GEICAM). No funding was received for the data analyses or the writing of this manuscript. Clinical trials GEICAM/9805 and BCIRG 001 were funded by Sanofi Aventis. GEICAM/9906 and GEICAM/2003-02 were partially funded by Bristol-Myers Squibb. These funding bodies were not involved in the collection and interpretation of the data or in the decision to publish. EA and MM were also supported by FEDER (RECTICC-RD12/0036/0076). We thank all the participating patients, clinicians, GEICAM and local research staff. We thank Hosanna Soler Vila, PhD, who provided medical writing services on behalf of GEICAM. Sí
Published: 2013

30. Oral verrucous hyperplasia due to repetitive chewing on lips

Author: Richard Alweis, Stephen Melnick, Salik Nazir, Noelle Juliano, Priya Rajagopalan, and SN, PR, SM & NJ were involved in overall drafting, design and writing of the manuscript. RA was involved in patient care, diagnosis and overall design of the manuscript. All authors have read and agreed with the final manuscript
Subjects: lcsh:Internal medicine, medicine.medical_specialty, business.industry, Verrucous carcinoma, 030206 dentistry, medicine.disease, Dermatology, Community hospital, Verrucous hyperplasia, 03 medical and health sciences, Premalignant lesions, verrucous hyperplasia, verrucous carcinoma, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal Medicine, Medicine, lcsh:RC31-1245, business, Imaging Column
Abstract: No abstract available. (Published: 6 July 2016) Citation: Journal of Community Hospital Internal Medicine Perspectives 2016, 6 : 31595 - http://dx.doi.org/10.3402/jchimp.v6.31595
Published: 2016
Full Text: View/download PDF

31. ‘‘The 3/3 Strategy’’: A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology

Author: Mari Mar Fernández, Roser Coca, Irene Garcia, Mari Carmen Aguilar, Gabriel Mestre, Margarita Alarcia, Gema Gallemi, José Antonio Martínez, Purificación Tortajada, Cristina Berbel, Jesús Rodríguez-Baño, Universidad de Sevilla. Departamento de Medicina, Universitat de Barcelona, [Mestre,G, Berbel,C, Tortajada,P] Nosocomial Infection Control Unit,Delfos Medical Center. Barcelona, Catalonia, Spain.[Alarcia,M, Coca,R, Gallemi,G, Garcia,I, Fernández,MM, Aguilar,MC] Supervisor Nursing Department, Delfos Medical Center. Barcelona, Catalonia, Spain.[Martínez,JA] Infectious Diseases Unit, Hospital Clinic. Barcelona. Catalonia, Spain. [Rodríguez-Baño,J] Infectious Diseases and Microbiology Unit, Universitary Hospital Virgen de Macarena. Seville, Spain., and In January 2011, Lab HARTMANN S.A, provided 200 bottles of hydroalcoholic gel and gel dispensers as an unrestricted collaboration for an educational program in infection control in Delfos Medical Center. GMR provides part-time consultancy activities for Lab HARTMANN S.A since April 2011. JRB received funding for research from Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III – co-financed by European Development Regional Fund ‘‘A way to achieve Europe’’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008). The other authors declare no conflicts of interest. This does not alter the authors, adherence to all the PLOS ONE policies on sharing data. The funders had no role in the design of the study, analysis of the data, writing of the manuscript, or decision to publish.
Subjects: Quality management, Non-Clinical Medicine, Epidemiology, Health Care Providers, Psychological intervention, Health Care::Environment and Public Health::Public Health::Public Health Practice::Communicable Disease Control::Infection Control [Medical Subject Headings], Infection control, Global Health, HH, Higiene hospitalària, Control d'infeccions, Hygiene, Medicine, Hand Hygiene, Clinical Epidemiology, Prospective Studies, Disciplines and Occupations::Social Sciences::Government::Federal Government::United States Government Agencies::United States Dept. of Health and Human Services::United States Public Health Service::Centers for Disease Control and Prevention (U.S.) [Medical Subject Headings], Epidemiological Methods, media_common, epidemiología, Public health, Multidisciplinary, Infecciones, Health Care::Health Care Quality, Access, and Evaluation::Quality Assurance, Health Care::Credentialing::Accreditation::Joint Commission on Accreditation of Healthcare Organizations [Medical Subject Headings], Quality Improvement, Hospitals, Infectious Diseases, Health Education and Awareness, Observational Studies, Enfermería, Public Health, Behavioral and Social Aspects of Health, Research Article, Healthcare associated infections, medicine.medical_specialty, Infectious Disease Control, Clinical Research Design, media_common.quotation_subject, Science, Mano, Healthcare-associated infections, World Health Organization, Environmental Epidemiology, Infectious Disease Epidemiology, Nursing, Intervention (counseling), Humans, Statistical Methods, Intensive care medicine, Infection Control, Health Care Policy, HAI, business.industry, Hospital hygiene, Control de Infecciones, Health Risk Analysis, Salut pública, Anatomy::Body Regions::Extremities::Upper Extremity::Hand [Medical Subject Headings], Diseases::Bacterial Infections and Mycoses::Infection [Medical Subject Headings], Preventive Medicine, Disciplines and Occupations::Health Occupations::Medicine::Public Health::Epidemiology [Medical Subject Headings], business, Disciplines and Occupations::Health Occupations::Nursing [Medical Subject Headings], Hand hygiene
Abstract: Background: Only multifaceted hospital wide interventions have been successful in achieving sustained improvements in hand hygiene (HH) compliance. Methodology/Principal Findings: Pre-post intervention study of HH performance at baseline (October 2007– December 2009) and during intervention, which included two phases. Phase 1 (2010) included multimodal WHO approach. Phase 2 (2011) added Continuous Quality Improvement (CQI) tools and was based on: a) Increase of alcohol hand rub (AHR) solution placement (from 0.57 dispensers/bed to 1.56); b) Increase in frequency of audits (three days every three weeks: ‘‘3/3 strategy’’); c) Implementation of a standardized register form of HH corrective actions; d) Statistical Process Control (SPC) as time series analysis methodology through appropriate control charts. During the intervention period we performed 819 scheduled direct observation audits which provided data from 11,714 HH opportunities. The most remarkable findings were: a) significant improvements in HH compliance with respect to baseline (25% mean increase); b) sustained high level (82%) of HH compliance during intervention; c) significant increase in AHRs consumption over time; c) significant decrease in the rate of healthcare-acquired MRSA; d) small but significant improvements in HH compliance when comparing phase 2 to phase 1 [79.5% (95% CI: 78.2–80.7) vs 84.6% (95% CI:83.8–85.4), p,0.05]; e) successful use of control charts to identify significant negative and positive deviations (special causes) related to the HH compliance process over time (‘‘positive’’: 90.1% as highest HH compliance coinciding with the ‘‘World hygiene day’’; and ‘‘negative’’:73.7% as lowest HH compliance coinciding with a statutory lay-off proceeding). Conclusions/Significance: CQI tools may be a key addition to WHO strategy to maintain a good HH performance over time. In addition, SPC has shown to be a powerful methodology to detect special causes in HH performance (positive and negative) and to help establishing adequate feedback to healthcare workers.
Published: 2012

32. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

Author: Francis Eustache, David Ames, Christopher C. Rowe, Nicolas Villain, Victor L. Villemagne, Olivier Salvado, Blandine Grassiot, Colin L. Masters, Pierrick Bourgeat, Ralph N. Martins, Kathryn A. Ellis, Gaël Chételat, Gareth Jones, Neuropsychologie cognitive et neuroanatomie fonctionnelles de la mémoire humaine, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Nuclear Medicine, Austin Health-Centre for Positron Emission Tomography (PET)-Austin Hospital [Melbourne], Austin Health, Preventative Health National Research Flagship, Commonwealth Scientific and Industrial Research Organisation (CSIRO)-Royal Brisbane and Women's Hospital-Information & Communication Technologies (ICT Centre)-The Australian e-Health Research Centre-BioMedIA, The Mental Health Research Institute, University of Melbourne, Centre of Psychiatry, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise Biomedical and Health Sciences-EDITH COWAN UNIVERSITY, Department of Medecine, University of Melbourne-Austin Health, Servier Institute (N.V. and B.G., partial), Inserm-Liliane Bettencourt MD-PhD Program (N.V., partial), Commonwealth Scientific Industrial Research Organization Preventative Health Flagship Program through the Australian Imaging, Biomarkers and Lifestyle flagship study of aging (AIBL) and Austin Hospital Medical Research Foundation, Neurosciences Victoria and the University of Melbourne. The funding sources had no input into the design of this study, the analysis of data or writing of the manuscript., Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -École pratique des hautes études ( EPHE ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Austin Health-Centre for Positron Emission Tomography (PET)-Austin Hospital, and Eustache, Francis
Subjects: Male, Oncology, Gerontology, Longitudinal study, positron emission tomography, Neocortex, Neuropsychological Tests, chemistry.chemical_compound, 0302 clinical medicine, Pittsburgh compound B, Carbon Radioisotopes, Longitudinal Studies, Cognitive decline, Brain Mapping, 0303 health sciences, Aniline Compounds, amyloid-b imaging, Alzheimer's disease, Disease Progression, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychology, medicine.medical_specialty, longitudinal imaging, Amyloid, Standardized uptake value, 03 medical and health sciences, Atrophy, mild cognitive impairment, Alzheimer Disease, Internal medicine, medicine, Humans, Cognitive Dysfunction, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Aged, 030304 developmental biology, Amyloid beta-Peptides, Case-control study, medicine.disease, Thiazoles, chemistry, Case-Control Studies, Positron-Emission Tomography, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], normal ageing, Neurology (clinical), Radiopharmaceuticals, 030217 neurology & neurosurgery
Abstract: International audience; Amyloid-β deposition in Alzheimer's disease is thought to start while individuals are still cognitively unimpaired and it is hypothesized that after an early phase of fast accumulation, a plateau is reached by the time of cognitive decline. However, few longitudinal Pittsburgh compound B-positron emission tomography studies have tested this hypothesis, and with conflicting results. The purpose of this work is to further our understanding of the dynamics of amyloid-β deposition in a large longitudinal cohort. A total of 32 patients with Alzheimer's disease, 49 subjects with mild cognitive impairment and 103 healthy controls underwent two Pittsburgh compound B-positron emission tomography scans 18 months apart. For each participant, a parametric map of Pittsburgh compound B-positron emission tomography rate of change was created [(follow-up scan - baseline scan)/follow-up duration] and entered in a voxelwise three-way analysis of covariance, with clinical status (healthy controls, mild cognitive impairment or Alzheimer's disease), disease progression (clinical conversion from healthy controls to mild cognitive impairment or Alzheimer's disease, or from mild cognitive impairment to Alzheimer's disease) and Pittsburgh compound B status (positive versus negative) as independent factors. Only a significant effect of the Pittsburgh compound B status was found: both Pittsburgh compound B-positive and -negative subjects showed a significant increase in amyloid-β deposition, with this increase being significantly higher in Pittsburgh compound B-positive individuals. This finding suggests either that Pittsburgh compound B-negative individuals have slower rates of amyloid-β accumulation than positive, or that the proportion of individuals showing significant increase in amyloid-β deposition, termed 'Pittsburgh compound B accumulators', is higher within the Pittsburgh compound B-positive group than within the Pittsburgh compound B-negative group. The bimodal distribution of the individual rates of neocortical amyloid-β accumulation observed support the existence of 'Pittsburgh compound B non-accumulators' and 'Pittsburgh compound B accumulators' and different clustering analyses led to a consistent threshold to separate these two subgroups (0.014-0.022 standardized uptake value ratio(pons)/year). The voxelwise three-way analysis of covariance was thus recomputed with the 'Pittsburgh compound B accumulators' only and the results were almost unchanged, with the Pittsburgh compound B-positive group showing higher accumulation than the Pittsburgh compound B-negative group. Finally, a significant negative correlation was found between Pittsburgh compound B rate of change and Pittsburgh compound B baseline burden, but only in the Pittsburgh compound B-positive group (r = -0.24; P = 0.025). Higher rates of amyloid-β deposition are associated with higher amyloid-β burden suggesting that amyloid-β deposition does not reach a plateau when cognitive impairments manifest but is instead an ongoing process present even at the Alzheimer's disease stage. amyloid-β accumulation also seems to slow down at the latest stages of the process, i.e. in participants with the highest amyloid burden. Furthermore, this study identified the existence of Pittsburgh compound 'accumulators' and 'non-accumulators', notably within the Pittsburgh compound B-negative group, which may be a relevant concept for future studies.
Published: 2012
Full Text: View/download PDF

33. Effects of photothermal kinetics and amplitude of photoperiod decrease on the induction of the reproduction cycle in female Eurasian perch Perca fluviatilis

Author: A. Abdulfatah, M. Marie, Pascal Fontaine, Patrick Kestemont, Jean-Noël Gardeur, Unité de Recherches Animal et Fonctionnalités des Produits Animaux (URAFPA), Institut National de la Recherche Agronomique (INRA)-Université de Lorraine (UL), Faculté Universitaire Notre Dame de la Paix, Partenaires INRAE, Institut National Polytechnique de Lorraine (INPL), and We would like to thank all members of the AFPA Research Unit for their active collaboration in this study and Dr Neil Wang for his help in the English writing of this manuscript. We are also indebted to the staff of the Department of Histology and Embryology (Faculty of Medicine, University of Namur, Belgium) for their huge contribution to the histological preparations (especially D. Van Vlaender, R. Deom and Prof. Y. Poumet). This study was partly funded by the European Union (project Percatech-COOP-CT-2004-512629) and the University of Aleppo (Syria).
Subjects: medicine.medical_specialty, media_common.quotation_subject, Photophase decrease, Photothermal kinetics, Aquatic Science, Biology, Oogenesis, 03 medical and health sciences, Animal science, Puberty control, Internal medicine, medicine, induction, 030304 developmental biology, media_common, photoperiodism, 0303 health sciences, Perch, Induction of ovarian cycle, [SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology, 04 agricultural and veterinary sciences, Oocyte, biology.organism_classification, Perca fluviatilis, Gonadosomatic Index, medicine.anatomical_structure, Endocrinology, fisheries, 040102 fisheries, 0401 agriculture, forestry, and fisheries, Vitellogenesis, Reproduction, Development of the gonads, marine and freshwater biology
Abstract: International audience; This study was designed to determine the effects of both rates of temperature and photoperiod decreases (further referred as photothermal kinetics) and amplitude of photoperiod decrease on the onset of the ovarian cycle in female Eurasian perch Perca fluviatilis. Two photothermal kinetics were applied on 16 groups of Eurasian perch breeders: one rapid (6 weeks) and one slow (16 weeks). For each photothermal kinetic, the effects of four amplitudes of photophase decrease (0, 1, 4 and 8 h) on gonadosomatic index (GSI), oocyte diameter (OD), oocyte stage and plasma oestradiol level (E2) were studied over a 168 day-period. Every combination (kinetic ∗ amplitude) was tested in duplicate. For both photothermal kinetics, females did not initiate oogenesis under a constant 17 L:7D photoperiod (0 h), (GSI ≤ 1%, OD ≤ 273 μm, mainly oocytes at primary growth or cortical alveoli stages and E2 ≤ 200 pg.mL−1 at day 168). By contrast, oogenesis was initiated when a 4 hour- or 8 hour photophase decrease was applied (GSI = 9–10%, OD = 620–665 μm, oocytes at exogenous vitellogenesis stage and E2 = 1000–1300 pg.mL−1 at day 168). When a one hour photophase decrease was applied, the female responded differently according to the photothermal kinetics. An inhibition (final GSI = 1.3% and OD = 268 μm) was observed under a rapid decrease (6 weeks), while a partial and delayed gonad development (final GSI = 4.9% and OD = 577 μm) was recorded under a slow decrease (16 week). This observation suggests that this 1-hour amplitude is close to the threshold of sensitivity below which females do not perceive photoperiod variations. This study shows that a high amplitude of photoperiod decrease (4 or 8 h) is required to induce oogenesis efficiently and that a constant photoperiod (17L:7D) can be used to control puberty and delay the onset of the reproductive cycle in female Eurasian perch. Finally, for the first time, a combined effect of both photothermal kinetics and amplitude of photophase decrease was identified in female Eurasian perch.
Published: 2011
Full Text: View/download PDF

34. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

Author: Angela Huth-Kühne, Francesco Baudo, Jean St-Louis, Midori Shima, Maria Eva Mingot Castellano, Craig M. Kessler, Hervé Levesque, Jørgen Ingerslev, Peter William Collins, [Huth-Kühne ,A] SRH Kurpfalzkrankenhaus Heidelberg gGmbH and Hemophilia Center, Heidelberg, Germany. [Baudo,F] Thrombosis and Hemostasis Unit, Niguarda Hospital, Milan, Italy. [Collins,P] Arthur Bloom Haemophilia Centre, University Hospital of Wales School of Medicine, Cardiff University, Cardiff, UK. [Ingerslev,J] Center for Hemophilia and Thrombosis, Skejby University Hospital, Department of Clinical Biochemistry, Aarhus, Denmark. [Kessler,CM] Georgetown University Hospital, Lombardi Cancer Center, Division of Hematology/Oncology, Washington, DC, USA. [Lévesque,H] Department of Internal Medicine, Centre Hospitalier Universitaire de Rouen-Boisguillaume, Rouen, France. [Mingot Castellano,EM] Regional University Hospital Carlos Haya, Division of Hematology, Málaga, Spain. [Shima,M] Department of Pediatrics, Nara Medical University, Nara, Japan. [St-Louis,J] Hématologie-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada., and Funding: support for literature searches, meeting organization and medical writing support for manuscript preparation were provided by Physicians World GmbH, Mannheim, Germany. Costs incurred for travel, hotel accommodation, meeting facilities, honoraria, remote communication and manuscript preparation were supported by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland.
Subjects: medicine.medical_specialty, Tratamiento medicamentoso combinado, Combination therapy, International Cooperation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination [Medical Subject Headings], Hemorrhage, Recommendations, Hemophilia A, Tiempo de tromboplastina parcial, Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia A [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Hemorrhage [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Disciplines and Occupations::Social Sciences::Internationality::International Cooperation [Medical Subject Headings], Pharmacotherapy, Internal medicine, Germany, Hemorragia, Cooperación Internacional, medicine, Humans, Geographicals::Geographic Locations::Europe::Germany [Medical Subject Headings], Acquired Factor VIII Deficiency, Intensive care medicine, health care economics and organizations, Hematology, medicine.diagnostic_test, business.industry, Inhibitors, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Blood Physiological Phenomena::Partial Thromboplastin Time [Medical Subject Headings], Bleeding, Autoantibody, Hemofilia A, Surgery, Acquired hemophilia, Treatment, Coagulation, Rituximab, Drug Therapy, Combination, Partial Thromboplastin Time, business, Partial thromboplastin time, medicine.drug
Abstract: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding and an isolated prolonged aPTT. AHA may, however, present without any bleeding symptoms, therefore an isolated prolonged aPTT should always be investigated further irrespective of the clinical findings. Control of acute bleeding is the first priority, and we recommend first-line therapy with bypassing agents such as recombinant activated FVII or activated prothrombin complex concentrate. Once the diagnosis has been achieved, immediate autoantibody eradication to reduce subsequent bleeding risk should be performed. We recommend initial treatment with corticosteroids or combination therapy with corticosteroids and cyclophosphamide and suggest second-line therapy with rituximab if first-line therapy fails or is contraindicated. In contrast to congenital hemophilia, no comparative studies exist to support treatment recommendations for patients with AHA, therefore treatment guidance must rely on the expertise and clinical experience of specialists in the field. The aim of this document is to provide a set of international practice guidelines based on our collective clinical experience in treating patients with AHA and contribute to improved care for this patient group. Yes
Published: 2009
Full Text: View/download PDF

35. The effect of post-discharge educational intervention on patients in achieving objectives in modifiable risk factors six months after discharge following an episode of acute coronary syndrome, (CAM-2 Project): a randomized controlled trial

Author: Juan José Gómez-Doblas, María I Santiago-Pérez, José María Cruz-Fernández, Iñaki Lekuona-Goya, Javier Muñiz, Nekane Murga-Eizagaetxebarría, Eduardo de Teresa-Galván ß, Alfonso Castro-Beiras, CAM2 Project working group., [Muñíz,J, Castro,A] Instituto Universitario de Ciencias de la Salud de la Universidad de A Coruña. Spain. [Gómez_Doblas,JJ, de Teresa-Galván B,E] Servicio de Cardiología. Hospital Universitario Virgen de la Victoria, Malaga. Spain. [Santiago-Pérez,MI] ODDS, S.L., La Coruña, Spain. [Lekuona-Goya,I] Servicio de Cardiología. Hospital Galdakao, Vizcaya, Spain. [Murga-Eizagaetxebarría,N] Servicio de Cardiología. Hospital de Basurto, Vizcaya, Spain. [Cruz-Fernández,JM] Servicio de Cardiología. Hospital Universitario Virgen Macarena, Sevilla, Spain. [Castro-Beiras,A] Servicio de Cardiología. Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde. La Coruña. Spain, and This study has been carried out thanks to funding from Merck, Sharp & Dohme (Spain) given unconditionally to the Instituto Universitario de Ciencias de la Salud, Universidad de A Coruña. The funding institution did not participate in the design, implementation or analysis of the study, nor in the writing of this manuscript. JM, JJGD, ETG and ACB are members of the Spanish network for cardiovascular research (RECAVA) of the Instituto de Salud Carlos III, as are the various researchers in the working group.
Subjects: Male, genetic structures, Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Acute Coronary Syndrome [Medical Subject Headings], Smoking Prevention, law.invention, Health Care::Environment and Public Health::Public Health::Public Health Practice::Secondary Prevention [Medical Subject Headings], Body Mass Index, Randomized controlled trial, Quality of life, law, Risk Factors, General Medicine, After discharge, Middle Aged, Lipids, Prevención, Hypertension, lcsh:R858-859.7, Female, riesgo cardiovascular, cardiovascular risk, medicine.medical_specialty, Acute coronary syndrome, Post discharge, Cardiovascular risk factors, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings], Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings], Chemicals and Drugs::Lipids [Medical Subject Headings], Health Promotion, lcsh:Computer applications to medicine. Medical informatics, Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Angina Pectoris [Medical Subject Headings], Patient Education as Topic, Intervention (counseling), medicine, Humans, Obesity, Acute Coronary Syndrome, sindrome coronario agudo, Exercise, Life Style, Aged, Physician-Patient Relations, business.industry, Research, Public Health, Environmental and Occupational Health, medicine.disease, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Spain, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Vital Signs::Blood Pressure [Medical Subject Headings], Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Health Behavior::Patient Compliance::Medication Adherence [Medical Subject Headings], Physical therapy, Patient Compliance, business, Body mass index, Follow-Up Studies
Abstract: Objectives We investigated whether an intervention mainly consisting of a signed agreement between patient and physician on the objectives to be reached, improves reaching these secondary prevention objectives in modifiable cardiovascular risk factors six-months after discharge following an acute coronary syndrome. Background There is room to improve mid-term adherence to clinical guidelines' recommendations in coronary heart disease secondary prevention, specially non-pharmacological ones, often neglected. Methods In CAM-2, patients discharged after an acute coronary syndrome were randomly assigned to the intervention or the usual care group. The primary outcome was reaching therapeutic objectives in various secondary prevention variables: smoking, obesity, blood lipids, blood pressure control, exercise and taking of medication. Results 1757 patients were recruited in 64 hospitals and 1510 (762 in the intervention and 748 in the control group) attended the six-months follow-up visit. After adjustment for potentially important variables, there were, between the intervention and control group, differences in the mean reduction of body mass index (0.5 vs. 0.2; p < 0.001) and waist circumference (1.6 cm vs. 0.6 cm; p = 0.05), proportion of patients who exercise regularly and those with total cholesterol below 175 mg/dl (64.7% vs. 56.5%; p = 0.001). The reported intake of medications was high in both groups for all the drugs considered with no differences except for statins (98.1% vs. 95.9%; p = 0.029). Conclusions At least in the short term, lifestyle changes among coronary heart disease patients are achievable by intensifying the responsibility of the patient himself by means of a simple and feasible intervention.
Published: 2010

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

35 results on '"writing of the manuscript"'

1. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity

2. Atopy modifies the association between inhaled corticosteroid use and lung function decline in patients with asthma

3. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort

4. Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy

5. Assessing Prevalence and Factors Related to Frailty in Community-Dwelling Older Adults: A Multinomial Logistic Analysis

6. Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper

7. The role of organization of care in GPs' prevention practice

8. Molecular Mimicry: a Paradigm of Host-Microbe Coevolution Illustrated by Legionella

9. Use of mental health supports by civilians exposed to the November 2015 terrorist attacks in Paris

10. Nocturia in patients with cognitive dysfunction: a systematic review of the literature

11. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial

12. Klebsiella pneumoniae carriage in low-income countries: antimicrobial resistance, genomic diversity and risk factors

13. Adherence to the Mediterranean Lifestyle and Desired Body Weight Loss in a Mediterranean Adult Population with Overweight: A PREDIMED-Plus Study

14. Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis

15. The effect of an online exercise programme on bone health in paediatric cancer survivors (iBoneFIT): study protocol of a multi-centre randomized controlled trial

17. Low serum DHEA-S is associated with impaired lung function in women

18. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)

19. High Prevalence of Leptospira spp. in Rodents in an Urban Setting in Madagascar

20. Effectiveness of a Mindfulness and Self-Compassion Standard Training Program versus an Abbreviated Training Program on Stress in Tutors and Resident Intern Specialists of Family and Community Medicine and Nursing in Spain

21. Efficacy of the In2Care® auto-dissemination device for reducing dengue transmission: study protocol for a parallel, two-armed cluster randomised trial in the Philippines

22. Blood lead level in infants and subsequent risk of malaria : a prospective cohort study in Benin, Sub-Saharan Africa

23. Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs

24. The 17β-Estradiol induced upregulation of the Adhesion G-protein coupled receptor (ADGRG7) is modulated by ESRα and SP1 complex

25. The use of FDI criteria in clinical trials on direct dental restorations: A scoping review

26. Roussouly's sagittal spino-pelvic morphotypes as determinants of gait in asymptomatic adult subjects

27. Evaluation of the performances of six commercial kits designed for dengue NS1 and anti-dengue IgM, IgG and IgA detection in urine and saliva clinical specimens

28. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency

29. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

30. Oral verrucous hyperplasia due to repetitive chewing on lips

31. ‘‘The 3/3 Strategy’’: A Successful Multifaceted Hospital Wide Hand Hygiene Intervention Based on WHO and Continuous Quality Improvement Methodology

32. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

33. Effects of photothermal kinetics and amplitude of photoperiod decrease on the induction of the reproduction cycle in female Eurasian perch Perca fluviatilis

34. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

35. The effect of post-discharge educational intervention on patients in achieving objectives in modifiable risk factors six months after discharge following an episode of acute coronary syndrome, (CAM-2 Project): a randomized controlled trial

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

35 results on '"writing of the manuscript"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources